[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Sol-Millennium Medical Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":193},{"warningLetters":4,"total":192},[5,35,57,78,98,117,137,155,174],{"id":6,"raw":7,"subject":15,"body_html":16,"body_text":17,"firm_name":18,"letter_id":19,"created_at":20,"fei_number":21,"letter_url":22,"updated_at":23,"action_type":24,"case_status":25,"posted_date":26,"marcs_cms_no":27,"product_type":28,"closeout_date":29,"issuing_office":30,"recipient_name":31,"body_fetched_at":32,"delivery_method":33,"recipient_title":21,"reference_number":21,"action_taken_date":34,"medical_device_id":21,"response_letter_date":21},1559,[8,9,10,11,12,13,14,13],"\u003Ctime datetime=\"2024-03-19T17:50:00Z\">03\u002F19\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-03-18T04:00:00Z\">03\u002F18\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsol-millennium-medical-inc-677524-03182024\">Sol-Millennium Medical, Inc.\u003C\u002Fa>"," Division of Medical Device and Radiological Health Operations Central","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA) Adulterated Device\u003Cbr \u002F>\r\n","","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsol-millennium-medical-inc-677524-12222025\">\u003Ctime datetime=\"2026-01-05T05:00:00Z\">01\u002F05\u002F2026\u003C\u002Ftime>\n\u003C\u002Fa>","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA) Adulterated Device","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Liang Lin\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Sol-Millennium Medical, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>311 S Wacker Drive Suite 4100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Chicago\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60606-6604\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Medical Device and Radiological Health Operations Central\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n     \n        \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS # 677524\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>March 18, 2024\u003Cbr>\n\u003Cbr>\nDear Mr. Lin:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, Sol-Millennium Medical, Inc., located at 311 S Wacker Drive, Suite 4100, Chicago, IL 60606-6604 on December 14, 2023, through December 20, 2023, investigators from the United States Food and Drug Administration (FDA) determined that your firm is a Specification Developer, Initial Importer, and a Complaint File Establishment of sterile and non-sterile syringes and needles intended for aspiration and injection of medications and fluids into the body. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>We received responses from you dated January 12, 2024, and January 29, 2024 concerning our investigator(s)’ observations noted on the FDA Form 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address these responses below, in relation to each of the noted violations, and any additional responses will be reviewed as part of your warning letter response.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved Device Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that the devices listed in \u003Cstrong>Table 1 \u003C\u002Fstrong>below are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution these devices with (1) major changes or modifications to the intended use, and\u002For (2) a change or modification in the device that could significantly affect the safety or effectiveness of the device without submitting a premarket notification to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3)(i)-(ii).\u003C\u002Fp>\n\n\u003Cp>Specifically, during our inspection you provided “EXH 039 - NACA PRODUCT LIST W 510K AND VENDORS_REVISED 15DEC2023.XLSX”. This document provides information related to the item number, product line, item description, whether the product is active, if Sol-M is the legal manufacturer, the PML 510k number and the prime manufacturer. Within this document you have listed product lines as covered by K101359. FDA’s investigation revealed that several of these product lines were not included under the clearance conditions established in K101359. The Inviro Medical Luer Lock Syringe was cleared under K101359 with the following indications for use: The InviroStripe Standard Luer Lock Syringes are used to inject medicines and vaccines into, or withdraw fluids from, the body. The FDA clearance for K101359 was based on a review of the 1, 3, 5, 10, 20, 30 and 60 mL Standard Luer Lock Syringes and the 510(k) Summary notes in the Device Description section that the syringes are packaged without needles. However, your firm’s promotion of the InviroStripe Standard Luer Lock Syringes provides evidence that you are marketing syringes with substantially different technological characteristics, namely luer lock syringes with blunt fill needles, luer lock syringes with pre-staked safety needles, luer lock syringes with exchangeable hypodermic needles, luer slip syringes, and eccentric tip syringes. Each of these different technological characteristics = constitutes a significant change or modification in design that could significantly alter the safety and effectiveness of the InviroStripe Standard Luer Lock Syringe without submitting a 510(k) to FDA. Specifically, switching from a luer lock to a luer slip or eccentric syringe tip, and including a new component such as a needle could result in the risk of patient harm such as inaccurate dosing, a leaking device, contamination, and a higher risk of inappropriate needle detachment. Changing the configuration of a syringe to include a needle without assurance of FDA review that this change was appropriately verified and validated could also lead to adverse health effects such as allergic reactions, skin irritation or inflammation, pain, fever, red blood cell damage that induces organ stress, and toxicity that leads to loss of organ function or failure.\u003C\u002Fp>\n\n\u003Cp>Your firm’s promotion of the InviroStripe Standard Luer Lock Syringe also provides evidence that you are marketing devices with a substantially different intended use under K101359, including syringes with a low dead space claim as well as accessories to syringes (see \u003Cstrong>Table 1\u003C\u002Fstrong>). These changes constitute a major change or modification to the device’s intended use, for which your firm lacks clearance or approval. Specifically, unsupported low dead space claims can result in patient harm such as dose inaccuracy and misleading users about the risk of disease transmission while using the device. Accessories such as those in Table 1 are not intended for withdrawal from or injection into the body, but are devices intended for use with syringes. Unsupported accessory device claims may lead to patient harm by increasing the existing risks of syringes when used together, including breakage, leaking, contamination, and dose inaccuracy.\u003C\u002Fp>\n\n\u003Cp>Your firm’s failure to submit 510(k)s for these devices has prevented FDA from evaluating the risks posed by these substantially different technological characteristics or from determining that these modified devices are as safe and effective as legally marketed syringes. Further, FDA has observed evidence of postmarket safety signals indicating product quality issues that have the potential to cause serious patient harm. Specifically, FDA is aware of multiple customer complaints regarding quality issues (e.g., cracks, breakage, luer connectivity failure, etc.) for syringes marketed by your firm.\u003C\u002Fp>\n\n\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency (21 CFR 807.81(b)). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your January 29, 2024, response indicates that you will file a new 510(k) with FDA to obtain a valid 510(k) clearance. You note that your firm will conduct and submit testing as part of the new 510(k) submission and have included a list of tests, based on the current version of the standards, that will be completed to support these changes. We cannot determine the adequacy of your firm’s response concerning the addition of the luer lock syringes with blunt fill needles, luer lock syringes with pre-staked safety needles, luer lock syringes with exchangeable hypodermic needles, luer slip syringes, eccentric tip syringes, dead space syringes, and syringe accessories because the results of this testing have not been provided.\u003C\u002Fp>\n\n\u003Cdiv>\n\u003Ctable>\n\t\u003Cthead>\n\t\t\u003Ctr>\n\t\t\t\u003Cth>Modification of cleared device\u003C\u002Fth>\n\t\t\t\u003Cth>Model Numbers\u003C\u002Fth>\n\t\t\u003C\u002Ftr>\n\t\u003C\u002Fthead>\n\t\u003Ctbody>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>Includes Fixed Needle\u003C\u002Ftd>\n\t\t\t\u003Ctd>181025\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>Includes Exchangeable Needle\u003C\u002Ftd>\n\t\t\t\u003Ctd>1812010, 1812015, 1812110, 1812115, 1812210, 1832010, 1832015, 1832110, 1832115, 1832210, 1832215, 1832310, 1832510, 1832515, 1832558, 1852010, 1852015, 1852115, 1852215, 11812558, 11812705, 11813005, 11832010, 11832015, 11832110, 11832115, 11832210, 11832215, 11832310, 11832315, 11832510, 11832558, 110101120011, 110101120012, 102115SN, 102215SN, 12310SN, 12315SN, 12510SN, 12515SN, 12558LDS, 12558SN, 12705SN, 13005SN, 181023L, 181025S, 1811815B, 1831815B, 1832110T, 1832210T, 1832310T, 1851815B, 1852010T, 1852110T, 32110SN, 32115SN, 32210SN, 32215SN, 32310SN, 32510SN, 32515SN, 32558SN, 52115SN, 52215SN, 900-7640, 900-7641, 900-7642, 900-7643, 900-7644, 900-7645, 900-7646, 900-7647, 900-7648, 900-7663, 900-7842, 900-7843, 900-7844, SYRS101235F, SYRS101255F, SYRS101272F, SYRS101392F, SYRS103205, SYRS103207, SYRS103215, SYRS103217, SYRS103225, SYRS103227, SYRS103235, SYRS103253, SYRS103255, SYRS105217, SYRS110207, SYRS110217, SYRS110227\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>Syringe has Luer Slip Tip\u003C\u002Ftd>\n\t\t\t\u003Ctd>180011, 180011LDS, 180020ST, 181025S, P180003ST, P180005ST, P180010ST, P180011, P180011LDS, P180011T, P180020ST, P180020ET, P180030ST,\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>Syringe has Eccentric Tip\u003C\u002Ftd>\n\t\t\t\u003Ctd>P180010ET, P180060ET, P180060ST\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>Syringe has Low Dead Space Claim\u003C\u002Ftd>\n\t\t\t\u003Ctd>12558LDS, 180011LDS, 181023L, 181025S, P180001PP, P180011LDS\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>Accessory\u003C\u002Ftd>\n\t\t\t\u003Ctd>110101150020, STCB01, STCB02, STCT01\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\u003C\u002Fdiv>\n\n\u003Cp>\u003Cstrong>Table 1\u003C\u002Fstrong> List of Sol-Millennium Medical Inc. piston syringes configurations implicated in this Warning Letter.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Registration &amp; Listing Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Under section 510 of the Act (21 U.S.C. § 360), manufacturers of medical devices are required to annually register with the FDA. Section 510 of the Act further requires domestic and foreign device establishments to submit their annual establishment registration and device listing information to FDA by electronic means [section 510(p) of the Act (21 U.S.C. § 360(p))] during the period beginning October 1st and ending December 31st of each year. Our records indicate that your firm has not fulfilled annual registration and listing requirements for fiscal year 2024.\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that your firm registered its Suwanee, Georgia site and listed activities as a Complaint File Establishment (CFE), Initial Importer, and Specification Developer (SPD) for your medical devices, including devices listed in \u003Cstrong>Table 1\u003C\u002Fstrong> above. However, it was discovered that your firm moved its global headquarters, including complaint handling activities, from Suwanee, GA to Chicago, IL in September 2020. It was also determined that your firm conducts design (specification development) activities at your Lugano, Switzerland and Shanghai, China sites. At the time of the inspection, these three facilities engaged in the manufacture of your devices were not registered with FDA, nor were any of your firm’s devices listed with their respective manufacturing facilities. During the inspection, your Quality Consultant explained that your firm thought it was acceptable to register and list your devices under the Suwanee, GA site since you maintain an office there for the purpose of receiving mail and accessing electronic records. Under 21 C.F.R. 807.20(a), an establishment “engaged in the manufacture, preparation, propagation, compounding, assembly, or processing of a device intended for human use shall register and submit listing information for those devices in commercial distribution”. The same is required for foreign device establishments under section 510(j)(1) (21 U.S.C. 360(j)(1)) and 21 CFR 807.40(a). To date, FDA has not received any response from your firm regarding our investigator(s)’ observations regarding registration.\u003C\u002Fp>\n\n\u003Cp>Therefore, all of your firm’s devices are misbranded within the meaning of section 502(o) of the Act (21 U.S.C. § 352(o)), in that the devices were not included in a list required by section 510(j) of the Act (21 U.S.C. § 360(j)).\u003C\u002Fp>\n\n\u003Cp>Additionally, it was also revealed during our inspection that your firm is still shipping product with addresses of the former headquarter locations in Lawrenceville, GA and Suwanee, GA. Under section 502(b) of the Act (21 U.S.C. § 352(b)) device labels are required to contain “the name and place of business of the manufacturer, packer, or distributer.” Under 21 CFR 801.1(e) you may list your principal place of business on the label rather than the actual location of manufacturing, packing, or distribution. To date, FDA has not received any response from your firm regarding our investigator(s)’ observations regarding address labeling. Therefore, because the Lawrenceville and Suwanee sites are neither the actual location of manufacturing, packing, or distribution and because neither is your principal place of business, any devices which bear these locations on the label are misbranded under section 502(b) of the Act.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Quality System Regulation Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at 21 CFR Part 820. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain procedures for the identification, documentation, validation, or where appropriate verification, review, and approval of design changes before their implementation, as required by 21 CFR 820.30(i).\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not applied the requirements of the \u003Cem>Medical Device Development Manual, GOP-0011, Rev 7 (Oct-30-2023), Section 9.5 \u003C\u002Fem>and the Engineering Change Request (ECR) and Engineering Change Order (ECO) Procedure, GOP-0018, Rev 6 (Sep-30-2023), to control the design changes before their implementation to your syringe devices. For example, there is no documentation, including, but not limited to, ECRs for the following activities of marketed devices:\u003C\u002Fp>\n\n\u003Cp>a. The change to combine the Sol-M Luer Lock Syringe with Blunt Fill Needle covered under K101359.\u003C\u002Fp>\n\n\u003Cp>b. The change to add a hypodermic and safety needle to the Luer Lock Syringe covered under K101359.\u003C\u002Fp>\n\n\u003Cp>c. The change to add 23, 30, and 31G needles to insulin and TB syringes covered under K132681.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. Your January 29, 2024, response indicated that you created ECR-2024-003 covering products concerning Item 1a above, ECR-2024-004 covering products concerning Item 1b above, and ECR-2024-005 covering products concerning Item 1c above. However, documentation or evidence of completed corrective actions was not provided, including corrective actions conducted as a result of your investigation into the root-cause(s) associated with the failure to implement your design change control procedures, and verification and\u002For validation that the corrective actions were effective, prior to their implementation, to prevent recurrence of these violations, as indicated in the \u003Cem>Global Quality Manual, GQM-0001, Rev. 18 (Oct-11-2023), Section 7.5.1\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>2. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). Specifically,\u003C\u002Fp>\n\n\u003Cp>a. Your firm did not initiate a complaint file for User Report MW511832 after being notified by FDA on June 16, 2023, of a complainant alleging a needle was embedded in the patient’s deep subcutaneous tissue. Your firm did not process the allegation as required in the \u003Cem>Complaint Handling Procedure, GOP-0006, Rev 14 (OCT-11-2023)\u003C\u002Fem>, which states “This procedure applies to all external and internal complaints handling in SOLM Globally.”\u003C\u002Fp>\n\n\u003Cp>b. Your firm did not implement the requirements of the \u003Cem>Complaint Handling Procedure, GOP-0006, Rev 14 (OCT-11-2023), Section 7.2.2\u003C\u002Fem>, to evaluate confirmed complaints for Medical Device Reporting to the FDA. For example,\u003Cbr>\n&nbsp; &nbsp; i. Complaint CF-244 (investigation completed October 12, 2023) involving reports of cracked SOL-M 10ml Luer Lock Syringe w\u002Fo Needle (Lot 04108072) was confirmed in the complaint investigation, but not evaluated for Medical Device Reporting to the FDA.\u003Cbr>\n&nbsp; &nbsp; ii. Complaint CF-284 (investigation completed November 09, 2023) involving reports of cracked SOL-M 20ml Eccentric Tip Syringe w\u002Fo Needle (bulk, sterile) (Lot 04212043) was confirmed in the complaint investigation, but not evaluated for Medical Device Reporting to the FDA.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. Your firm’s January 12, 2024, response indicates that your firm initiated a CAPA (CAPA-22) and a Complaint File (CF-380) in response to the observation, and the estimated completion date is February 15, 2023 [sic]. The response also states that your firm has corrected the reportability form by consolidating the reportability assessments of all major regions where your firm’s devices are marketed into a single form, GF-0080 (Event Reporting – Vigilance Decision Making Form, Rev 01), and has obsoleted the regional forms, GF-0081 and GF-0082. In addition, the response indicates your firm has filed the two (2) complaints CF-244 and CF-284 as Medical Device Reportable events with FDA, as of December 27, 2023, MDR numbers are 3014312726-2023-00010 and 3014312726-2023-00011, respectively. However, documentation or evidence of completed corrective actions was not provided. Your response included a blank copy of the updated GF-0080 form but failed to include completed updated GF-0080 forms documenting your firm’s reportability assessments. Supporting documentation, such as the completed CF-380, CAPA-22, and GF-0080, was not provided to show corrective actions have been completed. Also, your response indicates employee training is projected for completion by February 15, 2024, as part of your firm’s corrective actions. We cannot determine the adequacy of your firm’s response concerning the projected employee training because no training documents reflecting these updates to complaint handling have been provided.\u003C\u002Fp>\n\n\u003Cp>3. Failure to maintain adequate records of the investigation by the formally designated unit identified in 21 CFR 820.198(a) when an investigation is made, as required by 21 CFR 820.198(e).\u003C\u002Fp>\n\n\u003Cp>Records of complaint investigations do not include required information, including any unique device identifier (UDI) or universal product code (UPC). Specifically, your firm did not implement the requirements of the \u003Cem>Complaint Handling Procedure, GOP-0006, Rev 14 (OCT-11-2023), Section 4.12\u003C\u002Fem> and the \u003Cem>Corporate Vigilance Reporting Procedure, GOP-0007, Rev 8 (11-OCT-2023), Section 7.2.1\u003C\u002Fem>, to include the UDI on applicable records that are printed from your firm’s current electronic Quality Management System (e-QMS), including but not limited to Customer Feedback Reports, Complaint Investigation Forms and Official Response Letters. The UDI is also not recorded on the Event Reporting – MDR record which is uploaded to the applicable complaint record in the e-QMS. For example,\u003Cbr>\n&nbsp; &nbsp; i. CF-256 (09\u002F28\u002F23 - 10\u002F25\u002F23), involving the MONOJECT Hypodermic Safety Needle 25G*1\", does not include a recorded UDI on the Customer Feedback Report, Complaint Investigation Form, Official Response Letter, and the record of Event Reporting – MDR.\u003Cbr>\n&nbsp; &nbsp; ii. CF-295 (11\u002F16\u002F23 - 11\u002F27\u002F23), involving the SOL-CARE Safety Needle 25G*5\u002F8\", does not include a recorded UDI on the Official Response Letter and the record of Event Reporting – MDR.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. Your firm’s January 12, 2024, response indicates that your firm initiated a CAPA (CAPA-23) in response to the observation. In addition, your response indicates UDI information for all complaints will be updated where the UDI data is lacking and is estimated for completion by February 15, 2024. The response also states that the Event Reporting – Vigilance Decision Making Form, GF-0080, Rev 01 will require the UDI information for all product complaints logged into your firm’s e-QMS. Supporting documentation, such as CAPA-23, is not provided to demonstrate the corrective actions taken have been verified and\u002For validated as effective. Also, your response indicates your firm has updated the \u003Cem>Complaint Handling Work Instruction, GWI-0013, Rev 02 (08-JAN-2024)\u003C\u002Fem>, as part of your firm’s corrective actions. Your response did not include employee training requirements concerning the updated work instruction.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Medical Device Reporting Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm’s devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17.\u003C\u002Fp>\n\n\u003Cp>For example, during the inspection, your firm identified the document titled “Corporate Vigilance Reporting Procedure”, Doc No.: GOP-0007, Revision 08, dated 11-OCT- 2023 as its written MDR procedure. However, our review concluded that the procedure does not contain information that would indicate that it was an MDR procedure created in accordance with the requirements in 21 CFR 803.17.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response dated January 12, 2024, and conclude that it is not adequate. The response includes copies of the following procedural documents as your firm’s revised MDR procedure.\u003Cbr>\n\u003Cbr>\na. “Corporate Vigilance Reporting Procedure”, Doc No.: GOP-0007, Revision 10, dated 10-Jan-2024\u003Cbr>\nb. “Complaint Handling Procedure”, Doc No.: GOP-0006, Revision 15, dated: 05-Jan-2024\u003Cbr>\nc. “Event Reporting - Vigilance Decision Making Form”, Doc. No.: GF-0080, Revision 01, dated 05-Jan-2024\u003C\u002Fp>\n\n\u003Cp>After reviewing the revision, the following deficiencies were noted:&nbsp; &nbsp;\u003C\u002Fp>\n\n\u003Cp>i. The revision does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, the revision omits the definition of the term “reasonably suggests” found in 21 CFR 803.20(c)(1). The exclusion of the definition for the term from the revision may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\u003Cbr>\n&nbsp; &nbsp; ii. The revision does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, the revision does not include:\u003C\u002Fp>\n\n\u003Col>\n\t\u003Cli>Instructions for how to obtain and complete the FDA 3500A form.\u003C\u002Fli>\n\t\u003Cli>How your firm will ensure that all information reasonably known to you is submitted for each event. Specifically, which sections of the Form 3500A will need to be completed to include all information found in your firm’s possession and any information that becomes available as a result of a reasonable follow-up within your firm.\u003C\u002Fli>\n\u003C\u002Fol>\n\n\u003Cp>Your firm’s response dated January 29, 2024, did not address the noted procedural deficiencies.\u003C\u002Fp>\n\n\u003Cp>2. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2). For example,\u003C\u002Fp>\n\n\u003Cp>a. The information included for Complaint CF-37 and MedWatch report MW5118327 reasonably suggests that your firm’s needle malfunctioned (specifically, needle breakage) during use. A broken needle left in the patient would likely cause or contribute to a death or serious injury. There is no information included for the complaints that reasonably suggests that the needle left in the patient would not be likely to cause or contribute to a death or serious injury. Therefore, each event represents a reportable malfunction, as defined in 21 CFR 803.3. Your firm became aware of the referenced events on March 23, 2023, and June 16, 2023. However, the corresponding MDRs 3014312726-2023-00004 and 3014312726-2023-00005 were received by the FDA on June 6, 2023, and December 26, 2023, respectively, which exceeds the required 30-calendar day timeframe.\u003C\u002Fp>\n\n\u003Cp>b. The information included for Complaint COMP-2021-0097 reasonably suggests your firm’s safety blood collection needle malfunctioned (specifically, luer connectivity failure), resulting in the splattering of HIV-positive patient blood. Although there was no injury reported in this incident, there is no information included for the complaint that reasonably suggests that the malfunction the device would not be likely to cause or contribute to a death or serious injury, if it were to recur. Therefore, the malfunction referenced for the complaint represents a malfunction that would be likely to cause or contribute to a death or serious injury if it were to recur. Your firm became aware of the event on April 29, 2021, and the corresponding MDR 3014312726-2024-00001 was received by the FDA on January 2, 2024, which exceeds the required 30- calendar day timeframe.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response dated January 12, 2024, cannot be determined at this time. In the response, your firm mentions its root-cause investigation and plans to conduct a retrospective review of complaints received between January 2021 and December 2023. Your firm aims to submit any newly identified reportable events by February 15, 2024. As the planned corrective actions are still ongoing, we cannot determine the adequacy of the response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response dated January 29, 2024, did not address the noted deficiencies.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Melissa Michurski, Director of Compliance Branch, at oradevices2firmresponse@fda.hhs.gov. Refer to \u003Cstrong>CMS # 677524\u003C\u002Fstrong> when replying. If you have any questions about the contents of this letter, please contact Salvatore Randazzo, Compliance Officer, at 407-475-4712 or salvatore.randazzo@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Blake Bevill\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nDivision 2\u002FCentral\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Kellie B. Kelm, Ph.D.\u003Cbr>\nActing Office Director\u003Cbr>\nOHT3: Office of Gastrorenal, ObGyn,\u003Cbr>\nGeneral Hospital and Urology Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nLiang Lin\n\nRecipient Title\n\nCEO\n\nSol-Millennium Medical, Inc.\n\n311 S Wacker Drive Suite 4100\n\nChicago, IL 60606-6604\n\nUnited States\n\nIssuing Office:\n\nDivision of Medical Device and Radiological Health Operations Central\n\nUnited States\n\nSecondary Issuing Offices\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS # 677524\n\nMarch 18, 2024\n\nDear Mr. Lin:\n\nDuring an inspection of your firm, Sol-Millennium Medical, Inc., located at 311 S Wacker Drive, Suite 4100, Chicago, IL 60606-6604 on December 14, 2023, through December 20, 2023, investigators from the United States Food and Drug Administration (FDA) determined that your firm is a Specification Developer, Initial Importer, and a Complaint File Establishment of sterile and non-sterile syringes and needles intended for aspiration and injection of medications and fluids into the body. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nWe received responses from you dated January 12, 2024, and January 29, 2024 concerning our investigator(s)’ observations noted on the FDA Form 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address these responses below, in relation to each of the noted violations, and any additional responses will be reviewed as part of your warning letter response.\n\nUnapproved Device Violations\n\nOur inspection revealed that the devices listed in Table 1 below are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution these devices with (1) major changes or modifications to the intended use, and\u002For (2) a change or modification in the device that could significantly affect the safety or effectiveness of the device without submitting a premarket notification to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3)(i)-(ii).\n\nSpecifically, during our inspection you provided “EXH 039 - NACA PRODUCT LIST W 510K AND VENDORS_REVISED 15DEC2023.XLSX”. This document provides information related to the item number, product line, item description, whether the product is active, if Sol-M is the legal manufacturer, the PML 510k number and the prime manufacturer. Within this document you have listed product lines as covered by K101359. FDA’s investigation revealed that several of these product lines were not included under the clearance conditions established in K101359. The Inviro Medical Luer Lock Syringe was cleared under K101359 with the following indications for use: The InviroStripe Standard Luer Lock Syringes are used to inject medicines and vaccines into, or withdraw fluids from, the body. The FDA clearance for K101359 was based on a review of the 1, 3, 5, 10, 20, 30 and 60 mL Standard Luer Lock Syringes and the 510(k) Summary notes in the Device Description section that the syringes are packaged without needles. However, your firm’s promotion of the InviroStripe Standard Luer Lock Syringes provides evidence that you are marketing syringes with substantially different technological characteristics, namely luer lock syringes with blunt fill needles, luer lock syringes with pre-staked safety needles, luer lock syringes with exchangeable hypodermic needles, luer slip syringes, and eccentric tip syringes. Each of these different technological characteristics = constitutes a significant change or modification in design that could significantly alter the safety and effectiveness of the InviroStripe Standard Luer Lock Syringe without submitting a 510(k) to FDA. Specifically, switching from a luer lock to a luer slip or eccentric syringe tip, and including a new component such as a needle could result in the risk of patient harm such as inaccurate dosing, a leaking device, contamination, and a higher risk of inappropriate needle detachment. Changing the configuration of a syringe to include a needle without assurance of FDA review that this change was appropriately verified and validated could also lead to adverse health effects such as allergic reactions, skin irritation or inflammation, pain, fever, red blood cell damage that induces organ stress, and toxicity that leads to loss of organ function or failure.\n\nYour firm’s promotion of the InviroStripe Standard Luer Lock Syringe also provides evidence that you are marketing devices with a substantially different intended use under K101359, including syringes with a low dead space claim as well as accessories to syringes (see Table 1). These changes constitute a major change or modification to the device’s intended use, for which your firm lacks clearance or approval. Specifically, unsupported low dead space claims can result in patient harm such as dose inaccuracy and misleading users about the risk of disease transmission while using the device. Accessories such as those in Table 1 are not intended for withdrawal from or injection into the body, but are devices intended for use with syringes. Unsupported accessory device claims may lead to patient harm by increasing the existing risks of syringes when used together, including breakage, leaking, contamination, and dose inaccuracy.\n\nYour firm’s failure to submit 510(k)s for these devices has prevented FDA from evaluating the risks posed by these substantially different technological characteristics or from determining that these modified devices are as safe and effective as legally marketed syringes. Further, FDA has observed evidence of postmarket safety signals indicating product quality issues that have the potential to cause serious patient harm. Specifically, FDA is aware of multiple customer complaints regarding quality issues (e.g., cracks, breakage, luer connectivity failure, etc.) for syringes marketed by your firm.\n\nFor a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency (21 CFR 807.81(b)). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nThe adequacy of your firm’s response cannot be determined at this time. Your January 29, 2024, response indicates that you will file a new 510(k) with FDA to obtain a valid 510(k) clearance. You note that your firm will conduct and submit testing as part of the new 510(k) submission and have included a list of tests, based on the current version of the standards, that will be completed to support these changes. We cannot determine the adequacy of your firm’s response concerning the addition of the luer lock syringes with blunt fill needles, luer lock syringes with pre-staked safety needles, luer lock syringes with exchangeable hypodermic needles, luer slip syringes, eccentric tip syringes, dead space syringes, and syringe accessories because the results of this testing have not been provided.\n\nModification of cleared device\nModel Numbers\n\nIncludes Fixed Needle\n181025\n\nIncludes Exchangeable Needle\n1812010, 1812015, 1812110, 1812115, 1812210, 1832010, 1832015, 1832110, 1832115, 1832210, 1832215, 1832310, 1832510, 1832515, 1832558, 1852010, 1852015, 1852115, 1852215, 11812558, 11812705, 11813005, 11832010, 11832015, 11832110, 11832115, 11832210, 11832215, 11832310, 11832315, 11832510, 11832558, 110101120011, 110101120012, 102115SN, 102215SN, 12310SN, 12315SN, 12510SN, 12515SN, 12558LDS, 12558SN, 12705SN, 13005SN, 181023L, 181025S, 1811815B, 1831815B, 1832110T, 1832210T, 1832310T, 1851815B, 1852010T, 1852110T, 32110SN, 32115SN, 32210SN, 32215SN, 32310SN, 32510SN, 32515SN, 32558SN, 52115SN, 52215SN, 900-7640, 900-7641, 900-7642, 900-7643, 900-7644, 900-7645, 900-7646, 900-7647, 900-7648, 900-7663, 900-7842, 900-7843, 900-7844, SYRS101235F, SYRS101255F, SYRS101272F, SYRS101392F, SYRS103205, SYRS103207, SYRS103215, SYRS103217, SYRS103225, SYRS103227, SYRS103235, SYRS103253, SYRS103255, SYRS105217, SYRS110207, SYRS110217, SYRS110227\n\nSyringe has Luer Slip Tip\n180011, 180011LDS, 180020ST, 181025S, P180003ST, P180005ST, P180010ST, P180011, P180011LDS, P180011T, P180020ST, P180020ET, P180030ST,\n\nSyringe has Eccentric Tip\nP180010ET, P180060ET, P180060ST\n\nSyringe has Low Dead Space Claim\n12558LDS, 180011LDS, 181023L, 181025S, P180001PP, P180011LDS\n\nAccessory\n110101150020, STCB01, STCB02, STCT01\n\nTable 1 List of Sol-Millennium Medical Inc. piston syringes configurations implicated in this Warning Letter.\n\nRegistration & Listing Violations\n\nUnder section 510 of the Act (21 U.S.C. § 360), manufacturers of medical devices are required to annually register with the FDA. Section 510 of the Act further requires domestic and foreign device establishments to submit their annual establishment registration and device listing information to FDA by electronic means [section 510(p) of the Act (21 U.S.C. § 360(p))] during the period beginning October 1st and ending December 31st of each year. Our records indicate that your firm has not fulfilled annual registration and listing requirements for fiscal year 2024.\n\nOur inspection revealed that your firm registered its Suwanee, Georgia site and listed activities as a Complaint File Establishment (CFE), Initial Importer, and Specification Developer (SPD) for your medical devices, including devices listed in Table 1 above. However, it was discovered that your firm moved its global headquarters, including complaint handling activities, from Suwanee, GA to Chicago, IL in September 2020. It was also determined that your firm conducts design (specification development) activities at your Lugano, Switzerland and Shanghai, China sites. At the time of the inspection, these three facilities engaged in the manufacture of your devices were not registered with FDA, nor were any of your firm’s devices listed with their respective manufacturing facilities. During the inspection, your Quality Consultant explained that your firm thought it was acceptable to register and list your devices under the Suwanee, GA site since you maintain an office there for the purpose of receiving mail and accessing electronic records. Under 21 C.F.R. 807.20(a), an establishment “engaged in the manufacture, preparation, propagation, compounding, assembly, or processing of a device intended for human use shall register and submit listing information for those devices in commercial distribution”. The same is required for foreign device establishments under section 510(j)(1) (21 U.S.C. 360(j)(1)) and 21 CFR 807.40(a). To date, FDA has not received any response from your firm regarding our investigator(s)’ observations regarding registration.\n\nTherefore, all of your firm’s devices are misbranded within the meaning of section 502(o) of the Act (21 U.S.C. § 352(o)), in that the devices were not included in a list required by section 510(j) of the Act (21 U.S.C. § 360(j)).\n\nAdditionally, it was also revealed during our inspection that your firm is still shipping product with addresses of the former headquarter locations in Lawrenceville, GA and Suwanee, GA. Under section 502(b) of the Act (21 U.S.C. § 352(b)) device labels are required to contain “the name and place of business of the manufacturer, packer, or distributer.” Under 21 CFR 801.1(e) you may list your principal place of business on the label rather than the actual location of manufacturing, packing, or distribution. To date, FDA has not received any response from your firm regarding our investigator(s)’ observations regarding address labeling. Therefore, because the Lawrenceville and Suwanee sites are neither the actual location of manufacturing, packing, or distribution and because neither is your principal place of business, any devices which bear these locations on the label are misbranded under section 502(b) of the Act.\n\nQuality System Regulation Violations\n\nThis inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at 21 CFR Part 820. These violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain procedures for the identification, documentation, validation, or where appropriate verification, review, and approval of design changes before their implementation, as required by 21 CFR 820.30(i).\n\nSpecifically, your firm has not applied the requirements of the Medical Device Development Manual, GOP-0011, Rev 7 (Oct-30-2023), Section 9.5 and the Engineering Change Request (ECR) and Engineering Change Order (ECO) Procedure, GOP-0018, Rev 6 (Sep-30-2023), to control the design changes before their implementation to your syringe devices. For example, there is no documentation, including, but not limited to, ECRs for the following activities of marketed devices:\n\na. The change to combine the Sol-M Luer Lock Syringe with Blunt Fill Needle covered under K101359.\n\nb. The change to add a hypodermic and safety needle to the Luer Lock Syringe covered under K101359.\n\nc. The change to add 23, 30, and 31G needles to insulin and TB syringes covered under K132681.\n\nThe adequacy of your firm’s responses cannot be determined at this time. Your January 29, 2024, response indicated that you created ECR-2024-003 covering products concerning Item 1a above, ECR-2024-004 covering products concerning Item 1b above, and ECR-2024-005 covering products concerning Item 1c above. However, documentation or evidence of completed corrective actions was not provided, including corrective actions conducted as a result of your investigation into the root-cause(s) associated with the failure to implement your design change control procedures, and verification and\u002For validation that the corrective actions were effective, prior to their implementation, to prevent recurrence of these violations, as indicated in the Global Quality Manual, GQM-0001, Rev. 18 (Oct-11-2023), Section 7.5.1.\n\n2. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). Specifically,\n\na. Your firm did not initiate a complaint file for User Report MW511832 after being notified by FDA on June 16, 2023, of a complainant alleging a needle was embedded in the patient’s deep subcutaneous tissue. Your firm did not process the allegation as required in the Complaint Handling Procedure, GOP-0006, Rev 14 (OCT-11-2023), which states “This procedure applies to all external and internal complaints handling in SOLM Globally.”\n\nb. Your firm did not implement the requirements of the Complaint Handling Procedure, GOP-0006, Rev 14 (OCT-11-2023), Section 7.2.2, to evaluate confirmed complaints for Medical Device Reporting to the FDA. For example,\n\ni. Complaint CF-244 (investigation completed October 12, 2023) involving reports of cracked SOL-M 10ml Luer Lock Syringe w\u002Fo Needle (Lot 04108072) was confirmed in the complaint investigation, but not evaluated for Medical Device Reporting to the FDA.\n\nii. Complaint CF-284 (investigation completed November 09, 2023) involving reports of cracked SOL-M 20ml Eccentric Tip Syringe w\u002Fo Needle (bulk, sterile) (Lot 04212043) was confirmed in the complaint investigation, but not evaluated for Medical Device Reporting to the FDA.\n\nThe adequacy of your firm’s responses cannot be determined at this time. Your firm’s January 12, 2024, response indicates that your firm initiated a CAPA (CAPA-22) and a Complaint File (CF-380) in response to the observation, and the estimated completion date is February 15, 2023 [sic]. The response also states that your firm has corrected the reportability form by consolidating the reportability assessments of all major regions where your firm’s devices are marketed into a single form, GF-0080 (Event Reporting – Vigilance Decision Making Form, Rev 01), and has obsoleted the regional forms, GF-0081 and GF-0082. In addition, the response indicates your firm has filed the two (2) complaints CF-244 and CF-284 as Medical Device Reportable events with FDA, as of December 27, 2023, MDR numbers are 3014312726-2023-00010 and 3014312726-2023-00011, respectively. However, documentation or evidence of completed corrective actions was not provided. Your response included a blank copy of the updated GF-0080 form but failed to include completed updated GF-0080 forms documenting your firm’s reportability assessments. Supporting documentation, such as the completed CF-380, CAPA-22, and GF-0080, was not provided to show corrective actions have been completed. Also, your response indicates employee training is projected for completion by February 15, 2024, as part of your firm’s corrective actions. We cannot determine the adequacy of your firm’s response concerning the projected employee training because no training documents reflecting these updates to complaint handling have been provided.\n\n3. Failure to maintain adequate records of the investigation by the formally designated unit identified in 21 CFR 820.198(a) when an investigation is made, as required by 21 CFR 820.198(e).\n\nRecords of complaint investigations do not include required information, including any unique device identifier (UDI) or universal product code (UPC). Specifically, your firm did not implement the requirements of the Complaint Handling Procedure, GOP-0006, Rev 14 (OCT-11-2023), Section 4.12 and the Corporate Vigilance Reporting Procedure, GOP-0007, Rev 8 (11-OCT-2023), Section 7.2.1, to include the UDI on applicable records that are printed from your firm’s current electronic Quality Management System (e-QMS), including but not limited to Customer Feedback Reports, Complaint Investigation Forms and Official Response Letters. The UDI is also not recorded on the Event Reporting – MDR record which is uploaded to the applicable complaint record in the e-QMS. For example,\n\ni. CF-256 (09\u002F28\u002F23 - 10\u002F25\u002F23), involving the MONOJECT Hypodermic Safety Needle 25G*1\", does not include a recorded UDI on the Customer Feedback Report, Complaint Investigation Form, Official Response Letter, and the record of Event Reporting – MDR.\n\nii. CF-295 (11\u002F16\u002F23 - 11\u002F27\u002F23), involving the SOL-CARE Safety Needle 25G*5\u002F8\", does not include a recorded UDI on the Official Response Letter and the record of Event Reporting – MDR.\n\nThe adequacy of your firm’s responses cannot be determined at this time. Your firm’s January 12, 2024, response indicates that your firm initiated a CAPA (CAPA-23) in response to the observation. In addition, your response indicates UDI information for all complaints will be updated where the UDI data is lacking and is estimated for completion by February 15, 2024. The response also states that the Event Reporting – Vigilance Decision Making Form, GF-0080, Rev 01 will require the UDI information for all product complaints logged into your firm’s e-QMS. Supporting documentation, such as CAPA-23, is not provided to demonstrate the corrective actions taken have been verified and\u002For validated as effective. Also, your response indicates your firm has updated the Complaint Handling Work Instruction, GWI-0013, Rev 02 (08-JAN-2024), as part of your firm’s corrective actions. Your response did not include employee training requirements concerning the updated work instruction.\n\nMedical Device Reporting Violations\n\nOur inspection also revealed that your firm’s devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\n\n1. Failure to develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17.\n\nFor example, during the inspection, your firm identified the document titled “Corporate Vigilance Reporting Procedure”, Doc No.: GOP-0007, Revision 08, dated 11-OCT- 2023 as its written MDR procedure. However, our review concluded that the procedure does not contain information that would indicate that it was an MDR procedure created in accordance with the requirements in 21 CFR 803.17.\n\nWe reviewed your firm’s response dated January 12, 2024, and conclude that it is not adequate. The response includes copies of the following procedural documents as your firm’s revised MDR procedure.\n\na. “Corporate Vigilance Reporting Procedure”, Doc No.: GOP-0007, Revision 10, dated 10-Jan-2024\n\nb. “Complaint Handling Procedure”, Doc No.: GOP-0006, Revision 15, dated: 05-Jan-2024\n\nc. “Event Reporting - Vigilance Decision Making Form”, Doc. No.: GF-0080, Revision 01, dated 05-Jan-2024\n\nAfter reviewing the revision, the following deficiencies were noted:\n\ni. The revision does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, the revision omits the definition of the term “reasonably suggests” found in 21 CFR 803.20(c)(1). The exclusion of the definition for the term from the revision may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\n\nii. The revision does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, the revision does not include:\n\nInstructions for how to obtain and complete the FDA 3500A form.\n\nHow your firm will ensure that all information reasonably known to you is submitted for each event. Specifically, which sections of the Form 3500A will need to be completed to include all information found in your firm’s possession and any information that becomes available as a result of a reasonable follow-up within your firm.\n\nYour firm’s response dated January 29, 2024, did not address the noted procedural deficiencies.\n\n2. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2). For example,\n\na. The information included for Complaint CF-37 and MedWatch report MW5118327 reasonably suggests that your firm’s needle malfunctioned (specifically, needle breakage) during use. A broken needle left in the patient would likely cause or contribute to a death or serious injury. There is no information included for the complaints that reasonably suggests that the needle left in the patient would not be likely to cause or contribute to a death or serious injury. Therefore, each event represents a reportable malfunction, as defined in 21 CFR 803.3. Your firm became aware of the referenced events on March 23, 2023, and June 16, 2023. However, the corresponding MDRs 3014312726-2023-00004 and 3014312726-2023-00005 were received by the FDA on June 6, 2023, and December 26, 2023, respectively, which exceeds the required 30-calendar day timeframe.\n\nb. The information included for Complaint COMP-2021-0097 reasonably suggests your firm’s safety blood collection needle malfunctioned (specifically, luer connectivity failure), resulting in the splattering of HIV-positive patient blood. Although there was no injury reported in this incident, there is no information included for the complaint that reasonably suggests that the malfunction the device would not be likely to cause or contribute to a death or serious injury, if it were to recur. Therefore, the malfunction referenced for the complaint represents a malfunction that would be likely to cause or contribute to a death or serious injury if it were to recur. Your firm became aware of the event on April 29, 2021, and the corresponding MDR 3014312726-2024-00001 was received by the FDA on January 2, 2024, which exceeds the required 30- calendar day timeframe.\n\nThe adequacy of your firm’s response dated January 12, 2024, cannot be determined at this time. In the response, your firm mentions its root-cause investigation and plans to conduct a retrospective review of complaints received between January 2021 and December 2023. Your firm aims to submit any newly identified reportable events by February 15, 2024. As the planned corrective actions are still ongoing, we cannot determine the adequacy of the response.\n\nYour firm’s response dated January 29, 2024, did not address the noted deficiencies.\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent to: Melissa Michurski, Director of Compliance Branch, at oradevices2firmresponse@fda.hhs.gov. Refer to CMS # 677524 when replying. If you have any questions about the contents of this letter, please contact Salvatore Randazzo, Compliance Officer, at 407-475-4712 or salvatore.randazzo@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nBlake Bevill\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nDivision 2\u002FCentral\n\n\u002FS\u002F\n\nKellie B. Kelm, Ph.D.\n\nActing Office Director\n\nOHT3: Office of Gastrorenal, ObGyn,\n\nGeneral Hospital and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health","Sol-Millennium Medical, Inc.","sol-millennium-medical-inc-677524-03182024","2026-08-18T06:42:28.994808+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsol-millennium-medical-inc-677524-03182024","2026-10-26T08:10:01.109726+00:00","Warning Letter","Closed Out","2024-03-19","677524","Medical Devices","2026-01-05","Division of Medical Device and Radiological Health Operations Central","Liang Lin","2026-08-20T00:14:10.662+00:00","VIA UNITED PARCEL SERVICE","2024-03-18",{"id":36,"raw":37,"subject":42,"body_html":43,"body_text":44,"firm_name":45,"letter_id":46,"created_at":47,"fei_number":21,"letter_url":48,"updated_at":49,"action_type":24,"case_status":50,"posted_date":51,"marcs_cms_no":52,"product_type":53,"closeout_date":21,"issuing_office":41,"recipient_name":54,"body_fetched_at":55,"delivery_method":21,"recipient_title":21,"reference_number":21,"action_taken_date":56,"medical_device_id":21,"response_letter_date":21},2257,[38,39,40,41,42,13,13,13],"\u003Ctime datetime=\"2023-01-11T15:00:00Z\">01\u002F11\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-01-10T05:00:00Z\">01\u002F10\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedical-mikes-inc-647603-01102023\">Medical Mikes, Inc.\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mike Vanacoro\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Medical Mikes, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3393 Nutly Circle\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Yorktown Heights\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>10598\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:hello@medicalmikes.com\"> hello@medicalmikes.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n         \n          \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan> Federal Trade Commission\u003C\u002Fdd>\n\n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>RE: 647603\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: January 10, 2023\u003C\u002Fp>\n\n\u003Cp>RE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address https:\u002F\u002Fmedicalmikes.com\u002F on December 7, 2022, and January 6, 2023, respectively. The FDA has observed that your website offers cannabidiol (CBD) products for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&amp;C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&amp;C Act, 21 U.S.C. § 331(a) and (d)\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>Some examples of the claims on your website that establish the intended use of your products and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 include:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Health Benefits of CBD Oil\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The science behind CBD and health continues to grow every day, and emerging studies have linked CBD to a number of medicinal and health benefits. The application of CBD is broad and can help alleviate symptoms of many common ailments. . . .\u003C\u002Fp>\n\n\u003Cp>&nbsp; o Boosts Immune System: This 2020 review of existing research concluded that CBD could control immune responses to cytokines, chemokines, and regulatory cell induction, creating a potential use case for Covid treatment by preventing Cytokine Storms–the condition that transforms standard cases into life-threatening scenarios.” [From your September 2021 blog post titled “CBD FOR SENIORS: BEST PRODUCTS, BENEFITS, SAFETY, AND USES” https:\u002F\u002Fmedicalmikes.com\u002Fblogs\u002Fmedical-mikes-blog\u002Fcbd-for-seniors-best-products-benefits-safety-and-uses]\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Researchers Recommend CBD-Based Clinical Trials for Covid-19 Prevention\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Marsha Rosner of the University of Chicago and her team, who recently published a study in Science Advances, want to see CBD at the forefront of Covid-19 prevention studies. Why? Their widely circulated research indicated that highly potent oral CBD inhibits Covid infection in human lung cells and mice. According to their findings, CBD may work by inhibiting viral gene expression while boosting the body’s stress and immune responses.” [From your February 2022 blog post titled “COVID-19 AND CBD RESEARCH: THE LATEST FINDINGS AND TAKEAWAYS” https:\u002F\u002Fmedicalmikes.com\u002Fblogs\u002Fmedical-mikes-blog\u002Fcovid-19-and-cbd-research-the-latest-findings-and-takeaways]\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Lab Research Says CBDa and CBGa Can Stop Covid-19\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We’ve talked a lot about the potential of concentrated, oral CBD formulas for Covid-19. But what about other hemp compounds? . . .\u003C\u002Fp>\n\n\u003Cp>Study investigators found that, of hemp’s hundreds of cannabinoids, CBDa and CBGa exhibited the most powerful ability to inhibit the Covid protein from seizing human cells. Even more profound, these minor cannabinoids reduced viral infection loads (still, in a petri dish) by an astounding 50%.” [From your February 2022 blog post titled “COVID-19 AND CBD RESEARCH: THE LATEST FINDINGS AND TAKEAWAYS” https:\u002F\u002Fmedicalmikes.com\u002Fblogs\u002Fmedical-mikes-blog\u002Fcovid-19-and-cbd-research-the-latest-findings-and-takeaways]\u003C\u002Fp>\n\n\u003Cp>You should take immediate action to address this matter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&amp;C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&amp;C Act.\u003Cstrong> Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&amp;C Act. This list can be found at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\">http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>FTC Cease and Desist Demand:\u003C\u002Fstrong> In addition, it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the products identified above. Thus, any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence. You must immediately cease and desist making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $50,120 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Serena Viswanathan, Associate Director of the FTC’s Division of Advertising Practices, at sviswanathan@ftc.gov certifying that you have ceased making unsubstantiated claims for the product identified above. If you have any questions regarding compliance with the FTC Act, please contact Ms. Viswanathan at 202-326-3244.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CAPT Tina Smith\u003Cbr>\nActing Director\u003Cbr>\nOffice of Unapproved Drugs and Labeling Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>Sincerely,&nbsp;\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Serena Viswanathan\u003Cbr>\nAssociate Director\u003Cbr>\nDivision of Advertising Practices\u003Cbr>\nFederal Trade Commission\u003C\u002Fp>\n\n\u003Cp>______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMike Vanacoro\n\nMedical Mikes, Inc.\n\n3393 Nutly Circle\n\nYorktown Heights, NY 10598\n\nUnited States\n\nhello@medicalmikes.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nFederal Trade Commission\n\nWARNING LETTER\n\nRE: 647603\n\nDate: January 10, 2023\n\nRE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address https:\u002F\u002Fmedicalmikes.com\u002F on December 7, 2022, and January 6, 2023, respectively. The FDA has observed that your website offers cannabidiol (CBD) products for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-191 in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nSome examples of the claims on your website that establish the intended use of your products and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 include:\n\n“Health Benefits of CBD Oil\n\nThe science behind CBD and health continues to grow every day, and emerging studies have linked CBD to a number of medicinal and health benefits. The application of CBD is broad and can help alleviate symptoms of many common ailments. . . .\n\no Boosts Immune System: This 2020 review of existing research concluded that CBD could control immune responses to cytokines, chemokines, and regulatory cell induction, creating a potential use case for Covid treatment by preventing Cytokine Storms–the condition that transforms standard cases into life-threatening scenarios.” [From your September 2021 blog post titled “CBD FOR SENIORS: BEST PRODUCTS, BENEFITS, SAFETY, AND USES” https:\u002F\u002Fmedicalmikes.com\u002Fblogs\u002Fmedical-mikes-blog\u002Fcbd-for-seniors-best-products-benefits-safety-and-uses]\n\n“Researchers Recommend CBD-Based Clinical Trials for Covid-19 Prevention\n\nMarsha Rosner of the University of Chicago and her team, who recently published a study in Science Advances, want to see CBD at the forefront of Covid-19 prevention studies. Why? Their widely circulated research indicated that highly potent oral CBD inhibits Covid infection in human lung cells and mice. According to their findings, CBD may work by inhibiting viral gene expression while boosting the body’s stress and immune responses.” [From your February 2022 blog post titled “COVID-19 AND CBD RESEARCH: THE LATEST FINDINGS AND TAKEAWAYS” https:\u002F\u002Fmedicalmikes.com\u002Fblogs\u002Fmedical-mikes-blog\u002Fcovid-19-and-cbd-research-the-latest-findings-and-takeaways]\n\n“Lab Research Says CBDa and CBGa Can Stop Covid-19\n\nWe’ve talked a lot about the potential of concentrated, oral CBD formulas for Covid-19. But what about other hemp compounds? . . .\n\nStudy investigators found that, of hemp’s hundreds of cannabinoids, CBDa and CBGa exhibited the most powerful ability to inhibit the Covid protein from seizing human cells. Even more profound, these minor cannabinoids reduced viral infection loads (still, in a petri dish) by an astounding 50%.” [From your February 2022 blog post titled “COVID-19 AND CBD RESEARCH: THE LATEST FINDINGS AND TAKEAWAYS” https:\u002F\u002Fmedicalmikes.com\u002Fblogs\u002Fmedical-mikes-blog\u002Fcovid-19-and-cbd-research-the-latest-findings-and-takeaways]\n\nYou should take immediate action to address this matter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&C Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&C Act. This list can be found at http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products. Once you have taken actions to address the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nIf you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov.\n\nFTC Cease and Desist Demand: In addition, it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the products identified above. Thus, any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence. You must immediately cease and desist making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $50,120 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Serena Viswanathan, Associate Director of the FTC’s Division of Advertising Practices, at sviswanathan@ftc.gov certifying that you have ceased making unsubstantiated claims for the product identified above. If you have any questions regarding compliance with the FTC Act, please contact Ms. Viswanathan at 202-326-3244.\n\nSincerely,\n\n\u002FS\u002F\n\nCAPT Tina Smith\n\nActing Director\n\nOffice of Unapproved Drugs and Labeling Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\nSincerely,\n\n\u002FS\u002F\n\nSerena Viswanathan\n\nAssociate Director\n\nDivision of Advertising Practices\n\nFederal Trade Commission\n\n______________________\n\n1 As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.","Medical Mikes, Inc.","medical-mikes-inc-647603-01102023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedical-mikes-inc-647603-01102023","2026-10-26T08:09:23.002096+00:00","Issued","2023-01-11","647603","Drugs","Mike Vanacoro","2026-08-20T01:19:26.495+00:00","2023-01-10",{"id":58,"raw":59,"subject":64,"body_html":65,"body_text":66,"firm_name":67,"letter_id":68,"created_at":20,"fei_number":21,"letter_url":69,"updated_at":70,"action_type":24,"case_status":50,"posted_date":71,"marcs_cms_no":72,"product_type":28,"closeout_date":21,"issuing_office":73,"recipient_name":74,"body_fetched_at":75,"delivery_method":76,"recipient_title":21,"reference_number":21,"action_taken_date":77,"medical_device_id":21,"response_letter_date":21},1506,[60,61,62,63,64,13,13,13],"\u003Ctime datetime=\"2024-04-30T13:20:00Z\">04\u002F30\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-09-29T04:00:00Z\">09\u002F29\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fspectrum-medical-ltd-666543-09292023\">Spectrum Medical Ltd\u003C\u002Fa>","&quot;OHT2: Office of Cardiovascular Devices, Office of Product Evaluation and Quality&quot;","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Steve Turner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Spectrum Medical Ltd\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Harrier 4, Meteor Business Park, Cheltenham Road East\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gloucester, Gloucestershire\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>GL2 9QL\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United Kingdom\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>\"OHT2: Office of Cardiovascular Devices, Office of Product Evaluation and Quality\"\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 29, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Turner:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located at Harrier 4, Meteor Business Park, Cheltenham Road East, Gloucester, Gloucestershire, GL2 9QL United Kingdom on April 24, 2023 through April 27, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a medical device manufacturer of the Quantum Perfusion Systems family of devices, which include, but are not limited to, Quantum Oxygenators, Quantum SuperPAC tubing sets and cannulas, Quantum Perfusion Roller Pumps, Quantum Pump Frames, Quantum Power Supplies, Quantum Ventilation Modules, Quantum Smart Occluders, Quantum PureFlow Centrifugal Drives, and Quantum Heater Cooler. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>We received a response from you, dated May 5, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved-Device Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has reviewed your firm’s U.S. promotional material and user manuals for your Quantum Perfusion devices that were collected during the inspection and determined that, based on the labeling changes in the promotional material and user manuals, your firm markets several devices with indications beyond what FDA has cleared in your premarket notifications for these devices. As explained in Section V.A1 of the guidance document “\u003Cu>Deciding When to Submit a 510(k) for a Change to an Existing Device\u003C\u002Fu>” (“510(k) Modifications Guidance”) (https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fdeciding-when-submit-510k-change-existing-device), “most labeling changes that affect the substance, meaning, or scope of the indications for use could significantly affect safety or effectiveness and will require submission of a new 510(k).” As discussed below, your firm’s marketing of the above devices for use beyond the cleared 6 hours in cardiopulmonary bypass procedures and for use in the Intensive Care Unit (ICU) as well as patient transport constitute major changes to the scope of the indications for use that impact the intended use and significantly affect the safety or effectiveness of the devices. Therefore, per 21 CFR 807.81(a)(3)(ii), these changes required the submission of a new 510(k).\u003C\u002Fp>\n\n\u003Cp>We discuss below the specific instances where you market indications that go beyond what FDA has cleared in your premarket submissions for these products.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Quantum Pureflow Centrifugal Pumps:\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>Your Quantum Pureflow Centrifugal Pumps are cleared under marketing submissions K220842, K201320, K202169, and K192850. All cleared indications are similar and are for cardiopulmonary bypass (CPB) surgery, and following is an example of the cleared indications from K201320:\u003C\u002Fp>\n\n\u003Cp>The Quantum Perfusion Centrifugal Blood Pump CP22 with Integrated Sensors indicated for use exclusively with the Quantum Centrifugal Drive of Spectrum Medical is intended to pump the blood through an extracorporeal circuit and to monitor pressure for periods lasting less than 6 hours for the purpose of providing either: (i) Full or partial cardiopulmonary bypass (i.e., circuit includes an oxygenator) during open surgical procedures on the heart or great vessels; or (ii) Temporary circulatory bypass for diversion of flow around a planned disruption of the circulatory pathway necessary for open surgical procedures on the aorta or vena cava.\u003C\u002Fp>\n\n\u003Cp>All cleared indications for your Quantum Centrifugal Pumps specify that the pumps are indicated for open surgical procedures lasting 6 hours or less.\u003C\u002Fp>\n\n\u003Cp>However, on page 22, Section 3.1.1 Intended Use, of your “Quantum Perfusions Systems Hardware Manual, ECLS” which is distributed in the U.S., you state that “Quantum PureFlow Centrifugal Blood Pumps are indicated for use for 29 days. Refer to the Instructions for Use provided with Quantum PureFlow products.” The PureFlow Centrifugal Blood Pumps are not indicated for use for 29 days in the United States. They are indicated for use for up to 6 hours. Further, in your promotional material entitled “Flexible ECLS Solutions for the ICU and Patient Transport” which is material that is distributed in the U.S., you state on page 13 that the CP22 Centrifugal Drive System “can be used to support ECLS circuits” and “can be integrated with either the Charlotte and Toronto Perfusion Systems or directly connected to the new Quantum Workstation Elite during transport.” Your pump is cleared with an indication for open cardiac procedures. These procedures are not performed in the Intensive Care Unit (ICU) nor are they performed during transportation. This change constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>Quantum Roller Pumps and Quantum Power Supply Lite\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>The Quantum Roller Pumps and Quantum Power Supply Lite are cleared under premarket submission K173834 with the following indication:\u003C\u002Fp>\n\n\u003Cp>&nbsp; The Quantum Pump Console is indicated for use for up to 6 hours in cardiopulmonary bypass procedures, when used by a qualified medical professional who is experienced in the operation of this or similar equipment.\u003C\u002Fp>\n\n\u003Cp>However, you have listed both the pumps and the power supply lite as part of the ECLS system on page 21 of your “Quantum Perfusion Systems for ECLS Hardware Manual” which is distributed in the U.S.. Neither of these devices have been cleared with indications for any other form of extracorporeal life support (ECLS), other than CPB. You have a separate manual entitled “Quantum Perfusion Systems for CPB Hardware Manual.” Further, on page 14 of your promotional material entitled “Flexible ECLS Solutions for the ICU and Patient Transport” you list your roller pumps as part of your portfolio for ECLS in the ICU and patient transport. This change constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>Quantum SuperPAC with Side Port Technology and Quantum SuperPAC – Dual Lumen Technology\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>The SuperPAC family of cannulas are cleared under K221353 and K203067. All cleared indications for models in this family contain the following phrase:\u003C\u002Fp>\n\n\u003Cp>&nbsp; “intended for use…during extracorporeal life support procedures for periods of maximum 6 hours”\u003C\u002Fp>\n\n\u003Cp>On pages 22 and 23 of “Flexible ECLS Solutions for the ICU and Patient Transport” you state that the devices are used during extracorporeal life support and VA extracorporeal life support. You do not indicate that the device is indicated to be used only up to 6 hours. This change constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>Quantum Ventilation Module\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>On pages 10 and 11 of “Flexible ECLS Solutions for the ICU and Patient Transport” you list your Quantum Ventilation Module Lite, which, according to the product list provided to the FDA Inspector, was introduced into the U.S. market via a letter to file for your K202733 submission, which is for the Quantum Ventilation Module. In the premarket submission for K202733, the instructions for use provided for FDA review state that “the Quantum Ventilation Module has been designed to be used by experienced and trained clinicians as part of cardiopulmonary bypass therapy.” It further states that the equipment is “suitable for use in a hospital operating environment.” There is no discussion of use for patient transportation or use in the ICU. This change constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>Quantum SuperPAC Tubing Set\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>On page 16 “Flexible ECLS Solutions for the ICU and Patient Transport” you present your Quantum SuperPAC tubing system, which is cleared under K213540 for\u003C\u002Fp>\n\n\u003Cp>&nbsp; “use during cardiopulmonary bypass for a duration of up to 6 hours.”\u003C\u002Fp>\n\n\u003Cp>Cardiopulmonary bypass is not performed in the ICU or during patient transport. This change constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>Charlotte Frame Configuration\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that there are several Quantum Perfusion Frames sold in the U. S. and several have been introduced via letter to file to the submission K173834. One of these is the Charlotte frame configuration. Because it was introduced via a letter to file, FDA has not reviewed this frame configuration. The cleared indications for K173834 are:\u003C\u002Fp>\n\n\u003Cp>&nbsp; The Quantum Pump Console is indicated for use for up to 6 hours in cardiopulmonary bypass procedures, when used by a qualified medical professional who is experienced in the operation of this or similar equipment.\u003C\u002Fp>\n\n\u003Cp>However, the Charlotte frame is not listed in your “Quantum Perfusion Systems for CPB Hardware Manual” but it is listed in your “Quantum Perfusion Systems for ECLS Hardware Manual.” In addition, the Charlotte Perfusion System is presented on page 5 of “Flexible ECLS Solutions for the ICU and Patient Transport” and states it is “designed to maximize mobility within the ICU.” The Charlotte frame is being marketed with a different indication (i.e., ECLS other than CPB) than the frames cleared under K173834 (i.e., CPB). Specifically, frames that cannot safely and reliably support the configuration of devices needed for ECLS procedures other than CPB, raise serious public health concerns when used for those procedures, because failure of the frame to safely hold the devices during transportation or treatment of patients could result in serious patient harm or death. These devices are considered life sustaining and require a new premarket submission to assess safety and effectiveness.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response dated May 5, 2023, did not address the violations discussed above and, therefore, is not adequate.\u003Cbr>\n\u003Cbr>\nAccordingly, as discussed above, several of the Quantum Perfusion devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the devices as described and marketed. These devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution these devices with major changes or modifications to the intended use without submitting a new premarket notification to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3)(ii).\u003C\u002Fp>\n\n\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fdevice-advice-comprehensive-regulatory-assistance\u002Fhow-study-and-market-your-device. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Quality System Regulation (QSR) Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately establish and maintain procedures that include requirements for identifying the action(s) needed to correct and prevent recurrence of nonconforming product and other quality problems, as required by 21 CFR 820.100(a)(3).\u003C\u002Fp>\n\n\u003Cp>For example: CAPA number 342, which was opened on January 30, 2023, and closed on March 14, 2023, does not contain an adequate evaluation of actions needed to correct nonconforming product in the field. The CAPA notes that the issue will “be picked up during the general Pre-Install process, through existing checks, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> can be swapped out if\u002Fwhen required.” While this addresses the detectability and corrective actions once the failure occurs, there is no evidence of consideration given to the potential risks of the slipping\u002F failure to lock occurring during use and preventive actions that may be taken to prevent the issue from occurring. This does not identify the action(s) needed to correct the nonconforming product that is in the field, as required by 21 CFR 820.100(a)(3).\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response dated May 5, 2023, and concluded that it is not adequate with respect to CAPA 342, because it notes that a plan will be determined to verify and validate the CAPA actions and that the results will be documented once they are identified and completed. Your response does not address the risk of this nonconformity to fielded devices nor does it identify any plans for corrections or corrective actions for fielded devices.\u003C\u002Fp>\n\n\u003Cp>2. Failure to adequately establish and maintain procedures that include requirements for verifying or validating the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device, as required by 21 CFR 820.100(a)(4).\u003C\u002Fp>\n\n\u003Cp>For example: CAPA number 315, which was opened on April 12, 2022, and closed on November 11, 2022, does not contain a verification or validation plan and results that demonstrate that the corrective and preventive actions put in place to prevent the heat transfer fluid bag from breaking and leaking during shipping were effective. The packaging for the fluid bag was modified but there was no verification or validation that this change was effective in preventing the bag from being damaged in shipping. There is also no verification or validation that the corrective and preventive actions do not adversely affect the finished device.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response dated May 5, 2023, and concluded that it is not adequate. In this response, you provided an open CAPA, Number 357, that states effectiveness of the verification\u002Fvalidation plan and results will be documented. Your firm stated that you intended to submit your plans to verify and validate the actions taken in the CAPA by May 31, 2023, and results recorded by August 31, 2023, to FDA. In addition, SOP-018_V16 “Corrective and Preventive Action Procedure” will be reviewed and updated and the “Corrective and Preventative Action Report” will be updated to include an effectiveness of Verification\u002F Validation plan and results within the form.\u003C\u002Fp>\n\n\u003Cp>This response is not adequate because 1) the plans and results have not been provided to FDA as promised to verify that the actions identified in the CAPA have been verified and validated for effectiveness and that the actions do not adversely impact the final finished device and 2) there is no planned retrospective review to identify other CAPAs whose actions have been implemented without verification and validation.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have QSR violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov. \u003Cstrong>Refer to CMS case #666543\u003C\u002Fstrong> when replying. If you have any questions about the contents of this letter, please contact: Kathleen Grunder, Biomedical Engineer, at 301-796-2676 or Kathleen.Grunder@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Bram Zuckerman, MD\u003Cbr>\nDirector\u003Cbr>\nOHT 2: Office of Cardiovascular Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health for\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nColleen Powell, US Agent\u003Cbr>\nSpectrum Medical Inc\u003Cbr>\n481 Munn Road, Suite 180\u003Cbr>\nFort Mills, SC US 29715\u003Cbr>\nVia Email: Colleen.Powell@spectrummedical.com&gt;\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nSteve Turner\n\nRecipient Title\n\nChief Executive Officer\n\nSpectrum Medical Ltd\n\nHarrier 4, Meteor Business Park, Cheltenham Road East\n\nGloucester, Gloucestershire\n\nGL2 9QL\n\nUnited Kingdom\n\nIssuing Office:\n\n\"OHT2: Office of Cardiovascular Devices, Office of Product Evaluation and Quality\"\n\nUnited States\n\nWARNING LETTER\n\nSeptember 29, 2023\n\nDear Mr. Turner:\n\nDuring an inspection of your firm located at Harrier 4, Meteor Business Park, Cheltenham Road East, Gloucester, Gloucestershire, GL2 9QL United Kingdom on April 24, 2023 through April 27, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a medical device manufacturer of the Quantum Perfusion Systems family of devices, which include, but are not limited to, Quantum Oxygenators, Quantum SuperPAC tubing sets and cannulas, Quantum Perfusion Roller Pumps, Quantum Pump Frames, Quantum Power Supplies, Quantum Ventilation Modules, Quantum Smart Occluders, Quantum PureFlow Centrifugal Drives, and Quantum Heater Cooler. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nWe received a response from you, dated May 5, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations.\n\nUnapproved-Device Violations\n\nFDA has reviewed your firm’s U.S. promotional material and user manuals for your Quantum Perfusion devices that were collected during the inspection and determined that, based on the labeling changes in the promotional material and user manuals, your firm markets several devices with indications beyond what FDA has cleared in your premarket notifications for these devices. As explained in Section V.A1 of the guidance document “Deciding When to Submit a 510(k) for a Change to an Existing Device” (“510(k) Modifications Guidance”) (https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fdeciding-when-submit-510k-change-existing-device), “most labeling changes that affect the substance, meaning, or scope of the indications for use could significantly affect safety or effectiveness and will require submission of a new 510(k).” As discussed below, your firm’s marketing of the above devices for use beyond the cleared 6 hours in cardiopulmonary bypass procedures and for use in the Intensive Care Unit (ICU) as well as patient transport constitute major changes to the scope of the indications for use that impact the intended use and significantly affect the safety or effectiveness of the devices. Therefore, per 21 CFR 807.81(a)(3)(ii), these changes required the submission of a new 510(k).\n\nWe discuss below the specific instances where you market indications that go beyond what FDA has cleared in your premarket submissions for these products.\n\nQuantum Pureflow Centrifugal Pumps:\n\nYour Quantum Pureflow Centrifugal Pumps are cleared under marketing submissions K220842, K201320, K202169, and K192850. All cleared indications are similar and are for cardiopulmonary bypass (CPB) surgery, and following is an example of the cleared indications from K201320:\n\nThe Quantum Perfusion Centrifugal Blood Pump CP22 with Integrated Sensors indicated for use exclusively with the Quantum Centrifugal Drive of Spectrum Medical is intended to pump the blood through an extracorporeal circuit and to monitor pressure for periods lasting less than 6 hours for the purpose of providing either: (i) Full or partial cardiopulmonary bypass (i.e., circuit includes an oxygenator) during open surgical procedures on the heart or great vessels; or (ii) Temporary circulatory bypass for diversion of flow around a planned disruption of the circulatory pathway necessary for open surgical procedures on the aorta or vena cava.\n\nAll cleared indications for your Quantum Centrifugal Pumps specify that the pumps are indicated for open surgical procedures lasting 6 hours or less.\n\nHowever, on page 22, Section 3.1.1 Intended Use, of your “Quantum Perfusions Systems Hardware Manual, ECLS” which is distributed in the U.S., you state that “Quantum PureFlow Centrifugal Blood Pumps are indicated for use for 29 days. Refer to the Instructions for Use provided with Quantum PureFlow products.” The PureFlow Centrifugal Blood Pumps are not indicated for use for 29 days in the United States. They are indicated for use for up to 6 hours. Further, in your promotional material entitled “Flexible ECLS Solutions for the ICU and Patient Transport” which is material that is distributed in the U.S., you state on page 13 that the CP22 Centrifugal Drive System “can be used to support ECLS circuits” and “can be integrated with either the Charlotte and Toronto Perfusion Systems or directly connected to the new Quantum Workstation Elite during transport.” Your pump is cleared with an indication for open cardiac procedures. These procedures are not performed in the Intensive Care Unit (ICU) nor are they performed during transportation. This change constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval.\n\nQuantum Roller Pumps and Quantum Power Supply Lite\n\nThe Quantum Roller Pumps and Quantum Power Supply Lite are cleared under premarket submission K173834 with the following indication:\n\nThe Quantum Pump Console is indicated for use for up to 6 hours in cardiopulmonary bypass procedures, when used by a qualified medical professional who is experienced in the operation of this or similar equipment.\n\nHowever, you have listed both the pumps and the power supply lite as part of the ECLS system on page 21 of your “Quantum Perfusion Systems for ECLS Hardware Manual” which is distributed in the U.S.. Neither of these devices have been cleared with indications for any other form of extracorporeal life support (ECLS), other than CPB. You have a separate manual entitled “Quantum Perfusion Systems for CPB Hardware Manual.” Further, on page 14 of your promotional material entitled “Flexible ECLS Solutions for the ICU and Patient Transport” you list your roller pumps as part of your portfolio for ECLS in the ICU and patient transport. This change constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval.\n\nQuantum SuperPAC with Side Port Technology and Quantum SuperPAC – Dual Lumen Technology\n\nThe SuperPAC family of cannulas are cleared under K221353 and K203067. All cleared indications for models in this family contain the following phrase:\n\n“intended for use…during extracorporeal life support procedures for periods of maximum 6 hours”\n\nOn pages 22 and 23 of “Flexible ECLS Solutions for the ICU and Patient Transport” you state that the devices are used during extracorporeal life support and VA extracorporeal life support. You do not indicate that the device is indicated to be used only up to 6 hours. This change constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval.\n\nQuantum Ventilation Module\n\nOn pages 10 and 11 of “Flexible ECLS Solutions for the ICU and Patient Transport” you list your Quantum Ventilation Module Lite, which, according to the product list provided to the FDA Inspector, was introduced into the U.S. market via a letter to file for your K202733 submission, which is for the Quantum Ventilation Module. In the premarket submission for K202733, the instructions for use provided for FDA review state that “the Quantum Ventilation Module has been designed to be used by experienced and trained clinicians as part of cardiopulmonary bypass therapy.” It further states that the equipment is “suitable for use in a hospital operating environment.” There is no discussion of use for patient transportation or use in the ICU. This change constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval.\n\nQuantum SuperPAC Tubing Set\n\nOn page 16 “Flexible ECLS Solutions for the ICU and Patient Transport” you present your Quantum SuperPAC tubing system, which is cleared under K213540 for\n\n“use during cardiopulmonary bypass for a duration of up to 6 hours.”\n\nCardiopulmonary bypass is not performed in the ICU or during patient transport. This change constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval.\n\nCharlotte Frame Configuration\n\nOur inspection revealed that there are several Quantum Perfusion Frames sold in the U. S. and several have been introduced via letter to file to the submission K173834. One of these is the Charlotte frame configuration. Because it was introduced via a letter to file, FDA has not reviewed this frame configuration. The cleared indications for K173834 are:\n\nThe Quantum Pump Console is indicated for use for up to 6 hours in cardiopulmonary bypass procedures, when used by a qualified medical professional who is experienced in the operation of this or similar equipment.\n\nHowever, the Charlotte frame is not listed in your “Quantum Perfusion Systems for CPB Hardware Manual” but it is listed in your “Quantum Perfusion Systems for ECLS Hardware Manual.” In addition, the Charlotte Perfusion System is presented on page 5 of “Flexible ECLS Solutions for the ICU and Patient Transport” and states it is “designed to maximize mobility within the ICU.” The Charlotte frame is being marketed with a different indication (i.e., ECLS other than CPB) than the frames cleared under K173834 (i.e., CPB). Specifically, frames that cannot safely and reliably support the configuration of devices needed for ECLS procedures other than CPB, raise serious public health concerns when used for those procedures, because failure of the frame to safely hold the devices during transportation or treatment of patients could result in serious patient harm or death. These devices are considered life sustaining and require a new premarket submission to assess safety and effectiveness.\n\nYour firm’s response dated May 5, 2023, did not address the violations discussed above and, therefore, is not adequate.\n\nAccordingly, as discussed above, several of the Quantum Perfusion devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the devices as described and marketed. These devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution these devices with major changes or modifications to the intended use without submitting a new premarket notification to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3)(ii).\n\nFor a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fdevice-advice-comprehensive-regulatory-assistance\u002Fhow-study-and-market-your-device. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nQuality System Regulation (QSR) Violations\n\nThis inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\n\n1. Failure to adequately establish and maintain procedures that include requirements for identifying the action(s) needed to correct and prevent recurrence of nonconforming product and other quality problems, as required by 21 CFR 820.100(a)(3).\n\nFor example: CAPA number 342, which was opened on January 30, 2023, and closed on March 14, 2023, does not contain an adequate evaluation of actions needed to correct nonconforming product in the field. The CAPA notes that the issue will “be picked up during the general Pre-Install process, through existing checks, the (b)(4) can be swapped out if\u002Fwhen required.” While this addresses the detectability and corrective actions once the failure occurs, there is no evidence of consideration given to the potential risks of the slipping\u002F failure to lock occurring during use and preventive actions that may be taken to prevent the issue from occurring. This does not identify the action(s) needed to correct the nonconforming product that is in the field, as required by 21 CFR 820.100(a)(3).\n\nWe reviewed your firm’s response dated May 5, 2023, and concluded that it is not adequate with respect to CAPA 342, because it notes that a plan will be determined to verify and validate the CAPA actions and that the results will be documented once they are identified and completed. Your response does not address the risk of this nonconformity to fielded devices nor does it identify any plans for corrections or corrective actions for fielded devices.\n\n2. Failure to adequately establish and maintain procedures that include requirements for verifying or validating the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device, as required by 21 CFR 820.100(a)(4).\n\nFor example: CAPA number 315, which was opened on April 12, 2022, and closed on November 11, 2022, does not contain a verification or validation plan and results that demonstrate that the corrective and preventive actions put in place to prevent the heat transfer fluid bag from breaking and leaking during shipping were effective. The packaging for the fluid bag was modified but there was no verification or validation that this change was effective in preventing the bag from being damaged in shipping. There is also no verification or validation that the corrective and preventive actions do not adversely affect the finished device.\n\nWe reviewed your firm’s response dated May 5, 2023, and concluded that it is not adequate. In this response, you provided an open CAPA, Number 357, that states effectiveness of the verification\u002Fvalidation plan and results will be documented. Your firm stated that you intended to submit your plans to verify and validate the actions taken in the CAPA by May 31, 2023, and results recorded by August 31, 2023, to FDA. In addition, SOP-018_V16 “Corrective and Preventive Action Procedure” will be reviewed and updated and the “Corrective and Preventative Action Report” will be updated to include an effectiveness of Verification\u002F Validation plan and results within the form.\n\nThis response is not adequate because 1) the plans and results have not been provided to FDA as promised to verify that the actions identified in the CAPA have been verified and validated for effectiveness and that the actions do not adversely impact the final finished device and 2) there is no planned retrospective review to identify other CAPAs whose actions have been implemented without verification and validation.\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have QSR violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS case #666543 when replying. If you have any questions about the contents of this letter, please contact: Kathleen Grunder, Biomedical Engineer, at 301-796-2676 or Kathleen.Grunder@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nBram Zuckerman, MD\n\nDirector\n\nOHT 2: Office of Cardiovascular Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health for\n\nCC:\n\nColleen Powell, US Agent\n\nSpectrum Medical Inc\n\n481 Munn Road, Suite 180\n\nFort Mills, SC US 29715\n\nVia Email: Colleen.Powell@spectrummedical.com>","Spectrum Medical Ltd","spectrum-medical-ltd-666543-09292023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fspectrum-medical-ltd-666543-09292023","2026-10-26T08:10:02.82461+00:00","2024-04-30","666543","\"OHT2: Office of Cardiovascular Devices, Office of Product Evaluation and Quality\"","Steve Turner","2026-08-20T00:09:37.797+00:00","Via Email","2023-09-29",{"id":79,"raw":80,"subject":64,"body_html":86,"body_text":87,"firm_name":88,"letter_id":89,"created_at":20,"fei_number":21,"letter_url":90,"updated_at":91,"action_type":24,"case_status":25,"posted_date":92,"marcs_cms_no":93,"product_type":28,"closeout_date":94,"issuing_office":84,"recipient_name":95,"body_fetched_at":96,"delivery_method":21,"recipient_title":21,"reference_number":21,"action_taken_date":97,"medical_device_id":21,"response_letter_date":21},1671,[81,82,83,84,64,13,85,13],"\u003Ctime datetime=\"2023-12-26T14:20:00Z\">12\u002F26\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-09-22T04:00:00Z\">09\u002F22\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsonesta-medical-ab-667325-09222023\">Sonesta Medical AB\u003C\u002Fa>","Center for Devices and Radiological Health","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsonesta-medical-ab-667325-12042023\">\u003Ctime datetime=\"2024-02-28T05:00:00Z\">02\u002F28\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Pelin Sari\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Sonesta Medical AB\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Industrivagen 7\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>171 48\u003C\u002Fspan> \u003Cspan>Solna\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sweden\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)@sonestamedical.se\"> (b)(6)@sonestamedical.se\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 22, 2023\u003Cbr>\n\u003Cbr>\nDear Ms. Sari:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Solna, Sweden on June 5, 2023, through June 7, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Model 6210 radiographic table and Model S2 and S3 cystometric tables. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received responses from you dated June 1, 2023, August 11, 2023, and September 1, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specific requirements, as required by 21 CFR 820.50(a). Specifically, your firm’s current purchasing controls procedure, Supplier Evaluation, Rev 2, dated April 7, 2021, fails to define the frequency, type, and extent of control to exercise over suppliers, contractors, and consultants, based on the results of periodic evaluation. Additionally, your firm has not evaluated your contract repair\u002Fservicer, and the current contract Quality Assurance &amp; Regulatory Affairs consultant. Further, your firm failed to maintain records covering evaluation of the current contract Quality Assurance &amp; Regulatory Affairs consultant, who has been assisting your firm in overseeing and maintaining their Quality System procedures since the year 2020.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s responses dated June 1, 2023, August 11, 2023, and September 1, 2023, and conclude that they are not adequate. Your firm’s responses state that you have revised the Supplier Evaluation SOP 1) to include the frequency and\u002For period for evaluation of suppliers, contractors, and consultants, 2) to include the type and extent of control to exercise over suppliers, contractors and consultants based on the results of the periodic evaluation, 3) to include evaluation of the contract repair\u002Fservicer for the Model 6210 radiographic table and Model S2 and S3 cystometric tables, and 4) to include requirements for assessment of contractors, consultants, and evaluation of the current contract QA\u002FRA consultant. You state that appropriate staff has received training on the revised SOPs and forms. You have not completed the assessment and evaluation of the contract repair\u002Fservicer and your current contract Quality Assurance &amp; Regulatory Affairs consultant. Additionally, you have not conducted a retrospective review of related documentation to ensure compliance with updated procedures. Although your firm’s responses state that you have updated the Supplier Evaluation procedures, the revised procedures were not included for our evaluation.\u003C\u002Fp>\n\n\u003Cp>2. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). Specifically, your firm’s procedure, Process description deviation management, Rev 1, dated November 25, 2020, fails to define requirements for review of complaints to determine if they should be evaluated for Medical Device Reporting. Additionally, your firm’s complaint records do not consistently include the dates and results of investigation (e.g., covering failures involving welding breakages and safety switches). Further, a review of a sampling of complaint records found five of five records do not list the Unique Device Identification (UDI) code for the subject devices.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s responses dated June 1, 2023, August 11, 2023, and September 1, 2023, and conclude that they are not adequate. Your firm’s responses state that you have revised the complaint handling SOP to require dates and results of investigations and UDI code for subject devices. You also state that you have revised several forms including CAPA form and Non-Conformance Report form and trained the staff on the revised SOPs and forms. Also, you have not completed a review of complaints per the revised procedure to evaluate reportability for Medical Device Reporting and have not conducted a retrospective review of related documentation to ensure compliance with updated procedures. Although your responses state that you have updated the complaint handling procedures, the revised procedures were not included for our evaluation.\u003C\u002Fp>\n\n\u003Cp>3. Failure to establish and maintain procedures to ensure that the design requirements relating to a device are appropriate and address the intended use of the device, including the needs of the user and patient, as required by 21 CFR 820.30(c). Specifically, your firm does not have procedures for defining a mechanism to resolve incomplete, ambiguous, or conflicting design requirements.\u003C\u002Fp>\n\n\u003Cp>As of September 13, 2023, you have not provided a response to this observation.\u003C\u002Fp>\n\n\u003Cp>4. Failure to establish and maintain procedures for validating the device design under defined operating conditions on initial production units, lots, or batches, or their equivalents, as required by 21 CFR 820.30(g). Specifically, your firm’s design validation procedure, Rev 1, dated January 22, 2021, does not fully define requirements to ensure devices are designed to meet user needs and intended uses. For example, the procedure fails to a) require the evaluation to be carried out on initial production units or their equivalents; b) require the evaluation to be carried out under actual or simulated use conditions.\u003C\u002Fp>\n\n\u003Cp>As of September 13, 2023, you have not provided a response to this observation.\u003C\u002Fp>\n\n\u003Cp>5. Failure to establish and maintain procedures for the identification, documentation, validation or where appropriate verification, review, and approval of design changes before their implementation, as required by 21 CFR 820.30(i). Specifically, your firm does not have procedures for defining control for changes to existing device design requirements and design results, to include a) describing the changes and the reason for the changes; b) determining the need to verify and\u002For validate the changes; c) determining impact on the design risk analysis; d) determine any new regulatory requirements, such as premarket clearance or approval, as needed.\u003C\u002Fp>\n\n\u003Cp>As of September 13, 2023, you have not provided a response to this observation.\u003C\u002Fp>\n\n\u003Cp>6. Failure to establish and maintain procedures to control all documents, as required by 21 CFR 820.40. Specifically, your firm’s document controls procedure, Rev 1, dated December 15, 2020, does not require the approval of quality system documents to include the signature of the approving personnel and the date of that signature. Additionally, your firm has not fully implemented the current document controls procedure, which requires that you assign a unique document number to each quality system document, as multiple procedures do not feature a unique document number.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s responses dated June 1, 2023, August 11, 2023, and September 1, 2023, and conclude that they are not adequate. Your firm’s responses state that you have revised the document controls SOP to implement Acrobat sign and included the requirement of signature of approving personnel and date on the approval of quality system documents, as well as to include a unique document number to each quality system document. However, you have not conducted a retrospective review of related documentation to ensure compliance with updated procedures. Although your response states that you have updated the document controls procedures, the revised procedures were not included for our evaluation.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS case #667325 when replying. If you have any questions about the contents of this letter, please contact: Lu Jiang at +1(240)402-5779.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Robert Ochs, Ph.D.\u003Cbr>\nDirector\u003Cbr>\nOHT8: Office of Radiological Health\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>Cc:\u003Cbr>\nGreg Swanson\u003Cbr>\nUS Agent\u003Cbr>\nEmergo Global Representation LLC\u003Cbr>\n2500 Bee Cave Road, Building 1, Suite 300\u003Cbr>\nAustin, Texas 78746\u003Cbr>\nUSAgent@UL.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nPelin Sari\n\nRecipient Title\n\nChief Executive Officer\n\nSonesta Medical AB\n\nIndustrivagen 7\n\n171 48 Solna\n\nSweden\n\n(b)(6)@sonestamedical.se\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\n\nSeptember 22, 2023\n\nDear Ms. Sari:\n\nDuring an inspection of your firm located in Solna, Sweden on June 5, 2023, through June 7, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Model 6210 radiographic table and Model S2 and S3 cystometric tables. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received responses from you dated June 1, 2023, August 11, 2023, and September 1, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specific requirements, as required by 21 CFR 820.50(a). Specifically, your firm’s current purchasing controls procedure, Supplier Evaluation, Rev 2, dated April 7, 2021, fails to define the frequency, type, and extent of control to exercise over suppliers, contractors, and consultants, based on the results of periodic evaluation. Additionally, your firm has not evaluated your contract repair\u002Fservicer, and the current contract Quality Assurance & Regulatory Affairs consultant. Further, your firm failed to maintain records covering evaluation of the current contract Quality Assurance & Regulatory Affairs consultant, who has been assisting your firm in overseeing and maintaining their Quality System procedures since the year 2020.\n\nWe reviewed your firm’s responses dated June 1, 2023, August 11, 2023, and September 1, 2023, and conclude that they are not adequate. Your firm’s responses state that you have revised the Supplier Evaluation SOP 1) to include the frequency and\u002For period for evaluation of suppliers, contractors, and consultants, 2) to include the type and extent of control to exercise over suppliers, contractors and consultants based on the results of the periodic evaluation, 3) to include evaluation of the contract repair\u002Fservicer for the Model 6210 radiographic table and Model S2 and S3 cystometric tables, and 4) to include requirements for assessment of contractors, consultants, and evaluation of the current contract QA\u002FRA consultant. You state that appropriate staff has received training on the revised SOPs and forms. You have not completed the assessment and evaluation of the contract repair\u002Fservicer and your current contract Quality Assurance & Regulatory Affairs consultant. Additionally, you have not conducted a retrospective review of related documentation to ensure compliance with updated procedures. Although your firm’s responses state that you have updated the Supplier Evaluation procedures, the revised procedures were not included for our evaluation.\n\n2. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). Specifically, your firm’s procedure, Process description deviation management, Rev 1, dated November 25, 2020, fails to define requirements for review of complaints to determine if they should be evaluated for Medical Device Reporting. Additionally, your firm’s complaint records do not consistently include the dates and results of investigation (e.g., covering failures involving welding breakages and safety switches). Further, a review of a sampling of complaint records found five of five records do not list the Unique Device Identification (UDI) code for the subject devices.\n\nWe reviewed your firm’s responses dated June 1, 2023, August 11, 2023, and September 1, 2023, and conclude that they are not adequate. Your firm’s responses state that you have revised the complaint handling SOP to require dates and results of investigations and UDI code for subject devices. You also state that you have revised several forms including CAPA form and Non-Conformance Report form and trained the staff on the revised SOPs and forms. Also, you have not completed a review of complaints per the revised procedure to evaluate reportability for Medical Device Reporting and have not conducted a retrospective review of related documentation to ensure compliance with updated procedures. Although your responses state that you have updated the complaint handling procedures, the revised procedures were not included for our evaluation.\n\n3. Failure to establish and maintain procedures to ensure that the design requirements relating to a device are appropriate and address the intended use of the device, including the needs of the user and patient, as required by 21 CFR 820.30(c). Specifically, your firm does not have procedures for defining a mechanism to resolve incomplete, ambiguous, or conflicting design requirements.\n\nAs of September 13, 2023, you have not provided a response to this observation.\n\n4. Failure to establish and maintain procedures for validating the device design under defined operating conditions on initial production units, lots, or batches, or their equivalents, as required by 21 CFR 820.30(g). Specifically, your firm’s design validation procedure, Rev 1, dated January 22, 2021, does not fully define requirements to ensure devices are designed to meet user needs and intended uses. For example, the procedure fails to a) require the evaluation to be carried out on initial production units or their equivalents; b) require the evaluation to be carried out under actual or simulated use conditions.\n\nAs of September 13, 2023, you have not provided a response to this observation.\n\n5. Failure to establish and maintain procedures for the identification, documentation, validation or where appropriate verification, review, and approval of design changes before their implementation, as required by 21 CFR 820.30(i). Specifically, your firm does not have procedures for defining control for changes to existing device design requirements and design results, to include a) describing the changes and the reason for the changes; b) determining the need to verify and\u002For validate the changes; c) determining impact on the design risk analysis; d) determine any new regulatory requirements, such as premarket clearance or approval, as needed.\n\nAs of September 13, 2023, you have not provided a response to this observation.\n\n6. Failure to establish and maintain procedures to control all documents, as required by 21 CFR 820.40. Specifically, your firm’s document controls procedure, Rev 1, dated December 15, 2020, does not require the approval of quality system documents to include the signature of the approving personnel and the date of that signature. Additionally, your firm has not fully implemented the current document controls procedure, which requires that you assign a unique document number to each quality system document, as multiple procedures do not feature a unique document number.\n\nWe reviewed your firm’s responses dated June 1, 2023, August 11, 2023, and September 1, 2023, and conclude that they are not adequate. Your firm’s responses state that you have revised the document controls SOP to implement Acrobat sign and included the requirement of signature of approving personnel and date on the approval of quality system documents, as well as to include a unique document number to each quality system document. However, you have not conducted a retrospective review of related documentation to ensure compliance with updated procedures. Although your response states that you have updated the document controls procedures, the revised procedures were not included for our evaluation.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS case #667325 when replying. If you have any questions about the contents of this letter, please contact: Lu Jiang at +1(240)402-5779.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nRobert Ochs, Ph.D.\n\nDirector\n\nOHT8: Office of Radiological Health\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCc:\n\nGreg Swanson\n\nUS Agent\n\nEmergo Global Representation LLC\n\n2500 Bee Cave Road, Building 1, Suite 300\n\nAustin, Texas 78746\n\nUSAgent@UL.com","Sonesta Medical AB","sonesta-medical-ab-667325-09222023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsonesta-medical-ab-667325-09222023","2026-10-26T08:10:01.487143+00:00","2023-12-26","667325","2024-02-28","Pelin Sari","2026-08-20T00:25:09.984+00:00","2023-09-22",{"id":99,"raw":100,"subject":105,"body_html":106,"body_text":107,"firm_name":108,"letter_id":109,"created_at":110,"fei_number":21,"letter_url":111,"updated_at":112,"action_type":24,"case_status":50,"posted_date":113,"marcs_cms_no":114,"product_type":53,"closeout_date":21,"issuing_office":104,"recipient_name":21,"body_fetched_at":115,"delivery_method":76,"recipient_title":21,"reference_number":21,"action_taken_date":116,"medical_device_id":21,"response_letter_date":21},472,[101,102,103,104,105,13,13,13],"\u003Ctime datetime=\"2025-11-18T05:00:00Z\">11\u002F18\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-11-13T05:00:00Z\">11\u002F13\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedical-mega-717840-11132025\">Medical Mega\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Nonprescription\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Medical Mega\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>208 Fairmont Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jersey City\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07306\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Sales@medicalmega.com\"> Sales@medicalmega.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>November 13, 2025\u003C\u002Fp>\u003Cp>RE: 717840\u003C\u002Fp>\u003Cp>Medical Mega:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the internet address https:\u002F\u002Fwww.medicalmega.com. The FDA has observed that your website offers the following triclosan-containing consumer and health care antiseptic nonprescription drug products: “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 800 mL,” “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 1 Gallon,” and “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 1000 mL” (hereinafter “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan”) for sale in United States. Based on our review, these products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d). In addition, these products are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under sections 301 (d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are “drugs” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples from the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” product labeling, including your website, https:\u002F\u002Fwww.medicalmega.com, that provide evidence of the intended use (as defined in 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan”\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“Anti-microbial…Kills bacteria on contact…” [from your https:\u002F\u002Fmedicalmega.com\u002FAmeriWash-Antimicrobial-Lotion-Soap-with-Triclosan-1000-mL product page]\u003C\u002Fp>\u003Cp>Based on the above labeling evidence, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are intended for use as triclosan-containing consumer and health care antiseptic nonprescription drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for the drug products identified above.\u003C\u002Fp>\u003Cp>With respect to triclosan-containing consumer and health care antiseptic nonprescription drug products, such as the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan,” such products are subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, these products fall under section 505G(a)(5) of the FD&amp;C Act, 21 U.S.C. 355h(a)(5), because FDA has determined that topical consumer and health care antiseptic nonprescription drug products formulated with triclosan as an active ingredient are not GRASE under a final determination issued under 21 CFR part 330.1\u003C\u002Fp>\u003Cp>Therefore, these products are new drugs within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). No FDA-approved application pursuant to section 505 of the FD&amp;C Act is in effect for these drug products. Accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\u003Cp>In addition, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov, please include your firm name and the unique identifier “717840” in the subject line of the email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>_________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> On September 6, 2017, FDA issued a final rule establishing that certain ingredients for OTC topical consumer antiseptic wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (81 FR 61106). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(iii). On December 20, 2018, FDA issued a final rule establishing that certain ingredients for OTC health care antiseptic hand wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (82 FR 60474). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(vi). Under section 505G(k)(2)(A) of the FD&amp;C Act, the non-monograph conditions in 21 CFR 310.545 in effect on the day before the date of enactment of the CARES Act (i.e., March 26, 2020) were deemed to be a final administrative order. The final administrative order is entitled “Non-Monograph Conditions NM900: Drug Products Containing Certain Active Ingredients Offered Over-the-Counter for Certain Uses” (See Order ID OTC 000007, available at OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nMedical Mega\n\n208 Fairmont Ave\n\nJersey City, NJ 07306\n\nUnited States\n\nSales@medicalmega.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nNovember 13, 2025\nRE: 717840\nMedical Mega:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the internet address https:\u002F\u002Fwww.medicalmega.com. The FDA has observed that your website offers the following triclosan-containing consumer and health care antiseptic nonprescription drug products: “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 800 mL,” “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 1 Gallon,” and “Ameriderm AmeriWash Antimicrobial Lotion Soap with Triclosan 1000 mL” (hereinafter “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan”) for sale in United States. Based on our review, these products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d). In addition, these products are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under sections 301 (d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\nUnapproved New Drug and Misbranded Drug Violations\n“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are “drugs” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\nExamples from the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” product labeling, including your website, https:\u002F\u002Fwww.medicalmega.com, that provide evidence of the intended use (as defined in 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\n“Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan”\n“Anti-microbial…Kills bacteria on contact…” [from your https:\u002F\u002Fmedicalmega.com\u002FAmeriWash-Antimicrobial-Lotion-Soap-with-Triclosan-1000-mL product page]\nBased on the above labeling evidence, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are intended for use as triclosan-containing consumer and health care antiseptic nonprescription drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for the drug products identified above.\nWith respect to triclosan-containing consumer and health care antiseptic nonprescription drug products, such as the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan,” such products are subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, these products fall under section 505G(a)(5) of the FD&C Act, 21 U.S.C. 355h(a)(5), because FDA has determined that topical consumer and health care antiseptic nonprescription drug products formulated with triclosan as an active ingredient are not GRASE under a final determination issued under 21 CFR part 330.1\nTherefore, these products are new drugs within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p). No FDA-approved application pursuant to section 505 of the FD&C Act is in effect for these drug products. Accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. 331(d).\nIn addition, the “Ameriderm AmeriWash Antimicrobial Lotion Soaps with Triclosan” are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction.\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov, please include your firm name and the unique identifier “717840” in the subject line of the email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n_________________\n1 On September 6, 2017, FDA issued a final rule establishing that certain ingredients for OTC topical consumer antiseptic wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (81 FR 61106). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(iii). On December 20, 2018, FDA issued a final rule establishing that certain ingredients for OTC health care antiseptic hand wash nonprescription drug products, including triclosan, are not generally recognized as safe and effective (82 FR 60474). FDA’s final determination was codified in regulations at 21 CFR 310.545(a)(27)(vi). Under section 505G(k)(2)(A) of the FD&C Act, the non-monograph conditions in 21 CFR 310.545 in effect on the day before the date of enactment of the CARES Act (i.e., March 26, 2020) were deemed to be a final administrative order. The final administrative order is entitled “Non-Monograph Conditions NM900: Drug Products Containing Certain Active Ingredients Offered Over-the-Counter for Certain Uses” (See Order ID OTC 000007, available at OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F).","Medical Mega","medical-mega-717840-11132025","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmedical-mega-717840-11132025","2026-10-26T08:09:22.956521+00:00","2025-11-18","717840","2026-08-19T14:27:25.954+00:00","2025-11-13",{"id":118,"raw":119,"subject":124,"body_html":125,"body_text":126,"firm_name":127,"letter_id":128,"created_at":110,"fei_number":21,"letter_url":129,"updated_at":130,"action_type":24,"case_status":50,"posted_date":131,"marcs_cms_no":132,"product_type":28,"closeout_date":21,"issuing_office":84,"recipient_name":133,"body_fetched_at":134,"delivery_method":135,"recipient_title":21,"reference_number":21,"action_taken_date":136,"medical_device_id":21,"response_letter_date":21},63,[120,121,122,84,123,13,13,13],"\u003Ctime datetime=\"2026-06-30T04:00:00Z\">06\u002F30\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-05-20T04:00:00Z\">05\u002F20\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbmc-medical-co-ltd-725759-05202026\">BMC Medical Co., Ltd.\u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FPMA\u002FAdulterated\u002FMisbranded\u003Cbr \u002F>\r\n","CGMP\u002FQSR\u002FMedical Devices\u002FPMA\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jian Xu\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>BMC Medical Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>No. 16 Lize Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Room 10, 17F Building 4, Huiya Plaza\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Fengtai Qu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Beijing Shi\u003C\u002Fspan>, \u003Cspan>100073\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>CMS # 725759\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>May 20, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Xu:\u003C\u002Fp>\u003Cp>During an inspection of 3B Medical, Inc. (d.b.a. React Health, Inc.) located at 5475 Rings Road, Dublin, OH 43017 from December 1, 2025 through December 10, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is the specification developer and 510(k) owner of various ventilator devices that are imported to the United States by 3B Medical, Inc. This includes Auto-Adjusting Positive Airway Pressure (Auto-CPAP or APAP) ventilator devices, intended for the treatment of obstructive sleep apnea in adults, under the brand name of G3X APAP (G4600). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved Device Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>Our inspection revealed that your G3X APAP devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution these devices with significant changes or modifications without submitting a new premarket notification to FDA, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>Your firm has made significant changes or modifications to the design of the Luna® CPAP and Auto CPAP System which was granted clearance on September 8, 2016 under 510(k) number K153387. The inspection at 3B Medical, Inc. established that you are the design change authority and 510(k) owner of the device. For example, FDA has reviewed your firm’s nP3_Product System Verification Report_G3-2.11.01 and Design change evaluation report, Project code: nP3 for the Luna G3 APAP, Model LG3600, approved on March 12, 2025, which revealed that the firmware\u002Fsoftware was updated with additional recognition features, i.e., (1) Flow Limitation, (2) Respiratory Effort-Related Arousals (RERA), and (3) Periodic breathing, to distinguish between central hypopnea and obstructive hypopnea events.\u003C\u002Fp>\u003Cp>Furthermore, the sound abatement system of the cleared Luna APAP devices was modified to ‘\u003Cstrong>(b)(4)\u003C\u002Fstrong>’ or ‘\u003Cstrong>(b)(4)\u003C\u002Fstrong>’ and a new \u003Cstrong>(b)(4)\u003C\u002Fstrong> was added to the cleared Luna APAP device to match the sound reduction as a result of the material change. Additionally, the Printed Circuit Board Assembly (PCBA) includes a new \u003Cstrong>(b)(4)\u003C\u002Fstrong> chip compatible with the new algorithm and new data structure master control software. These design modifications to the cleared Luna APAP appear to have given rise to a new model branded as G3X APAP. These changes could significantly affect safety or effectiveness because they are significant changes in the design and materials of these devices. The firmware update introduced new detection algorithms capable of distinguishing between central and obstructive hypopnea events, which affects the accuracy of event classification and the data available to clinicians for evaluating therapy effectiveness and informing future therapy adjustments. The removal of \u003Cstrong>(b)(4)\u003C\u002Fstrong> represents a material change to the gas pathway that raises biocompatibility concerns, and when combined with the addition of a new \u003Cstrong>(b)(4)\u003C\u002Fstrong>, these changes could affect the overall pressure and flow profile of the device, thereby impacting therapy delivery. The addition of a new \u003Cstrong>(b)(4)\u003C\u002Fstrong> PCBA chip and updated master control software introduces potential implications for electrical safety and overall device performance. Collectively, these changes represent significant modifications in device design, materials, and software that could significantly affect the safety and effectiveness of the device.\u003C\u002Fp>\u003Cp>FDA’s regulations at 21 CFR 807.81(a)(3)(i) provide that submission of a 510(k) is required for “a change or modification in the device that could significantly affect the safety or effectiveness of the device, e.g., a significant change or modification in design, material, chemical composition, energy source, or manufacturing process.” Thus, the G3X APAP is misbranded under 502(o) because of your failure to submit the required premarket notification for the modifications. FDA requests that your firm cease any activities that result in the misbranding or adulteration of your devices.\u003C\u002Fp>\u003Cp>For further explanation on the need for a new premarket notification, or \"510(k),\" for changes to the intended use or design affecting safety and effectiveness, consult the guidance document \"Deciding When to Submit a 510(k) for a Change to an Existing Device — Guidance for Industry and Food and Drug Administration Staff (fda.gov).\" The “Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program Guidance for Industry and Food and Drug Administration Staff,” is also recommended for obtaining FDA feedback on the 510(k) submission for the G3 X APAP devices.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Correction and Removals Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>Our inspection also revealed that your firm’s Luna G3 APAP devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals.\u003C\u002Fp>\u003Cp>Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to submit a Report required by 21 CFR 806.10 to FDA, within 10 working days of initiating the correction or removal. For example: your Luna G3 APAP devices with firmware G3-2.00.76 could cause the Luna G3 APAP device to unexpectedly shut down during use, which causes loss of therapy for patients with obstructive sleep apnea. You communicated with 3B (React Health) in \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The action of updating the firmware to G3-2.00.77 is a medical device correction or removal initiated to reduce a risk to health posed by the device or to remedy a violation of the Act caused by the device which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA.\u003C\u002Fp>\u003Cp>Your firm has not submitted a Report of Correction or Removal to FDA for the firmware update to G3-2.00.77 as of May 19, 2026.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts.\u003C\u002Fp>\u003Cp>On February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. The inspection of 3B Medical on December 1, 2025 to December 10, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, should any corrective actions you propose or implement relate to device current good manufacturing practice (CGMP) requirements, they must be made pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 725759” when replying. If you have any questions about the contents of this letter, please contact: Sargum Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara A. Marsden\u003Cbr>Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC:\u003Cbr>\u003Cstrong>(b)(4), (b)(6)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJian Xu\n\nRecipient Title\n\nPresident\n\nBMC Medical Co., Ltd.\n\nNo. 16 Lize Road\n\nRoom 10, 17F Building 4, Huiya Plaza\n\nFengtai Qu\n\nBeijing Shi, 100073\n\nChina\n\n(b)(6)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 725759\nMay 20, 2026\nDear Mr. Xu:\nDuring an inspection of 3B Medical, Inc. (d.b.a. React Health, Inc.) located at 5475 Rings Road, Dublin, OH 43017 from December 1, 2025 through December 10, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is the specification developer and 510(k) owner of various ventilator devices that are imported to the United States by 3B Medical, Inc. This includes Auto-Adjusting Positive Airway Pressure (Auto-CPAP or APAP) ventilator devices, intended for the treatment of obstructive sleep apnea in adults, under the brand name of G3X APAP (G4600). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\nUnapproved Device Violations\nOur inspection revealed that your G3X APAP devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution these devices with significant changes or modifications without submitting a new premarket notification to FDA, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nYour firm has made significant changes or modifications to the design of the Luna® CPAP and Auto CPAP System which was granted clearance on September 8, 2016 under 510(k) number K153387. The inspection at 3B Medical, Inc. established that you are the design change authority and 510(k) owner of the device. For example, FDA has reviewed your firm’s nP3_Product System Verification Report_G3-2.11.01 and Design change evaluation report, Project code: nP3 for the Luna G3 APAP, Model LG3600, approved on March 12, 2025, which revealed that the firmware\u002Fsoftware was updated with additional recognition features, i.e., (1) Flow Limitation, (2) Respiratory Effort-Related Arousals (RERA), and (3) Periodic breathing, to distinguish between central hypopnea and obstructive hypopnea events.\nFurthermore, the sound abatement system of the cleared Luna APAP devices was modified to ‘(b)(4)’ or ‘(b)(4)’ and a new (b)(4) was added to the cleared Luna APAP device to match the sound reduction as a result of the material change. Additionally, the Printed Circuit Board Assembly (PCBA) includes a new (b)(4) chip compatible with the new algorithm and new data structure master control software. These design modifications to the cleared Luna APAP appear to have given rise to a new model branded as G3X APAP. These changes could significantly affect safety or effectiveness because they are significant changes in the design and materials of these devices. The firmware update introduced new detection algorithms capable of distinguishing between central and obstructive hypopnea events, which affects the accuracy of event classification and the data available to clinicians for evaluating therapy effectiveness and informing future therapy adjustments. The removal of (b)(4) represents a material change to the gas pathway that raises biocompatibility concerns, and when combined with the addition of a new (b)(4), these changes could affect the overall pressure and flow profile of the device, thereby impacting therapy delivery. The addition of a new (b)(4) PCBA chip and updated master control software introduces potential implications for electrical safety and overall device performance. Collectively, these changes represent significant modifications in device design, materials, and software that could significantly affect the safety and effectiveness of the device.\nFDA’s regulations at 21 CFR 807.81(a)(3)(i) provide that submission of a 510(k) is required for “a change or modification in the device that could significantly affect the safety or effectiveness of the device, e.g., a significant change or modification in design, material, chemical composition, energy source, or manufacturing process.” Thus, the G3X APAP is misbranded under 502(o) because of your failure to submit the required premarket notification for the modifications. FDA requests that your firm cease any activities that result in the misbranding or adulteration of your devices.\nFor further explanation on the need for a new premarket notification, or \"510(k),\" for changes to the intended use or design affecting safety and effectiveness, consult the guidance document \"Deciding When to Submit a 510(k) for a Change to an Existing Device — Guidance for Industry and Food and Drug Administration Staff (fda.gov).\" The “Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program Guidance for Industry and Food and Drug Administration Staff,” is also recommended for obtaining FDA feedback on the 510(k) submission for the G3 X APAP devices.\nCorrection and Removals Violations\nOur inspection also revealed that your firm’s Luna G3 APAP devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals.\nSignificant violations include, but are not limited to, the following:\n1. Failure to submit a Report required by 21 CFR 806.10 to FDA, within 10 working days of initiating the correction or removal. For example: your Luna G3 APAP devices with firmware G3-2.00.76 could cause the Luna G3 APAP device to unexpectedly shut down during use, which causes loss of therapy for patients with obstructive sleep apnea. You communicated with 3B (React Health) in (b)(4) to (b)(4). The action of updating the firmware to G3-2.00.77 is a medical device correction or removal initiated to reduce a risk to health posed by the device or to remedy a violation of the Act caused by the device which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA.\nYour firm has not submitted a Report of Correction or Removal to FDA for the firmware update to G3-2.00.77 as of May 19, 2026.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts.\nOn February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. The inspection of 3B Medical on December 1, 2025 to December 10, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, should any corrective actions you propose or implement relate to device current good manufacturing practice (CGMP) requirements, they must be made pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage: https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 725759” when replying. If you have any questions about the contents of this letter, please contact: Sargum Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara A. Marsden\nDirector\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC:\n(b)(4), (b)(6)","BMC Medical Co., Ltd.","bmc-medical-co-ltd-725759-05202026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbmc-medical-co-ltd-725759-05202026","2026-10-26T08:08:06.951272+00:00","2026-06-30","725759","Jian Xu","2026-08-19T04:32:13.877+00:00","VIA Electronic Mail","2026-05-20",{"id":138,"raw":139,"subject":124,"body_html":143,"body_text":144,"firm_name":145,"letter_id":146,"created_at":147,"fei_number":21,"letter_url":148,"updated_at":149,"action_type":24,"case_status":50,"posted_date":150,"marcs_cms_no":151,"product_type":28,"closeout_date":21,"issuing_office":84,"recipient_name":152,"body_fetched_at":153,"delivery_method":33,"recipient_title":21,"reference_number":21,"action_taken_date":154,"medical_device_id":21,"response_letter_date":21},954,[140,141,142,84,124,13,13,13],"\u003Ctime datetime=\"2025-04-22T04:00:00Z\">04\u002F22\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-04-04T04:00:00Z\">04\u002F04\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ficu-medical-702535-04042025\">ICU Medical\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Vivek Jain\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>ICU Medical\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>951 Calle Amanecer\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>San Clemente\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92673\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS 702535\u003C\u002Fp>\u003Cp>April 04, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Jain:\u003C\u002Fp>\u003Cp>During an inspection of Smiths Medical ASD (acquired by your firm ICU Medical in January 2022) FEI: 3012307300 located at 6000 Nathan Lane N., Minneapolis, Minnesota on July 23, 2024, through August 9, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), each of these products is a device because it is an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, which is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Our inspection revealed that the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not for these devices have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at\u003Cbr>http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>You currently have clearance, dated August 29, 2011, for a version of the Medfusion® Model 4000 Syringe Infusion Pump which was cleared under K111386 as a Class II device under 21 CFR 880.5725. You also currently have clearance, dated February 1, 2013, for a version of the CADD® Solis VIP Ambulatory Infusion Pump which was cleared under K111275 as a Class II device under 21 CFR 880.5725. However, your firm has failed to submit a premarket notification submission to FDA for significant changes or modifications that could significantly affect the safety or effectiveness of these devices, as required by 21 CFR 807.81(a)(3)(i).\u003C\u002Fp>\u003Cp>In particular, since their last respective clearances, you made multiple changes to the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump that could significantly affect the safety or effectiveness of these devices, including the \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the Medfusion® Model 4000 Syringe Infusion Pump as well as \u003Cstrong>(b)(4)\u003C\u002Fstrong> changes for both the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump. Specifically, these modifications included \u003Cstrong>(b)(4)\u003C\u002Fstrong> changes to address \u003Cstrong>(b)(4)\u003C\u002Fstrong> identified via adverse event reports and \u003Cstrong>(b)(4)\u003C\u002Fstrong> changes to \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Such modifications can significantly impact the functionality of the device with respect to the infusion pumps delivery profile, alarm functionality, etc., and affect the device’s risk profile for risks related to under- or over-infusion, delay in therapy, incomplete therapy, or false alarms leading to adverse health effects for patients such as overdose, volume overload, or cardiorespiratory compromise. Your documentation collected during the recent inspection describing the 510(k) risk-benefit analysis for the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump indicates that these changes were implemented after the most recent clearances of the devices as noted above. Further, you have disseminated updated software \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which includes the changes described above, in response to a Class I recall intended to remediate the cause(s) of the recall impacting delivery of fluids, false alarms, therapy interruption, etc. However, you have not yet submitted 510(k)s as required by 21 CFR 807.81(a)(3)(i). Adding a statement to your labeling that the device software has not undergone FDA review is not sufficient.\u003C\u002Fp>\u003Cp>Furthermore, in the regulatory change impact assessment for the Medfusion® Model 4000 Syringe Infusion Pump software update dated April 28, 2023, you identified that a risk-based assessment of the changed device identified new risks or significantly modified risks. Further, you identified that the change either creates or necessitates a new risk control measure or modification of an existing risk control measure for a hazardous situation that could result in significant harm. The changes that you made to the risk control measures in an effort to mitigate the hazards that were the basis for a Class I recall were not submitted to FDA in a required 510(k) even though your own procedure indicates that submission of a 510(k) would be required in this situation. However, you only documented to the file that you had made the change and did not submit the required 510(k).\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address the violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which should address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent to: Melissa Michurski, Assistant Director at CDRHenforcement@fda.hhs.gov. Please include in the subject line, CMS case # 702535 when replying. If you have any questions about the contents of this letter, please contact: Demetria Lueneburg, Compliance Officer at Demetria.Lueneburg@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility or associated with your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew G. Hillebrenner\u003Cbr>Deputy Director\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nVivek Jain\n\nRecipient Title\n\nCEO\n\nICU Medical\n\n951 Calle Amanecer\n\nSan Clemente, CA 92673\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS 702535\nApril 04, 2025\nDear Mr. Jain:\nDuring an inspection of Smiths Medical ASD (acquired by your firm ICU Medical in January 2022) FEI: 3012307300 located at 6000 Nathan Lane N., Minneapolis, Minnesota on July 23, 2024, through August 9, 2024, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), each of these products is a device because it is an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, which is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nOur inspection revealed that the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not for these devices have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at\nhttp:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nYou currently have clearance, dated August 29, 2011, for a version of the Medfusion® Model 4000 Syringe Infusion Pump which was cleared under K111386 as a Class II device under 21 CFR 880.5725. You also currently have clearance, dated February 1, 2013, for a version of the CADD® Solis VIP Ambulatory Infusion Pump which was cleared under K111275 as a Class II device under 21 CFR 880.5725. However, your firm has failed to submit a premarket notification submission to FDA for significant changes or modifications that could significantly affect the safety or effectiveness of these devices, as required by 21 CFR 807.81(a)(3)(i).\nIn particular, since their last respective clearances, you made multiple changes to the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump that could significantly affect the safety or effectiveness of these devices, including the (b)(4) for the Medfusion® Model 4000 Syringe Infusion Pump as well as (b)(4) changes for both the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump. Specifically, these modifications included (b)(4) changes to address (b)(4) identified via adverse event reports and (b)(4) changes to (b)(4) and (b)(4). Such modifications can significantly impact the functionality of the device with respect to the infusion pumps delivery profile, alarm functionality, etc., and affect the device’s risk profile for risks related to under- or over-infusion, delay in therapy, incomplete therapy, or false alarms leading to adverse health effects for patients such as overdose, volume overload, or cardiorespiratory compromise. Your documentation collected during the recent inspection describing the 510(k) risk-benefit analysis for the Medfusion® Model 4000 Syringe Infusion Pump and CADD® Solis VIP Ambulatory Infusion Pump indicates that these changes were implemented after the most recent clearances of the devices as noted above. Further, you have disseminated updated software (b)(4), which includes the changes described above, in response to a Class I recall intended to remediate the cause(s) of the recall impacting delivery of fluids, false alarms, therapy interruption, etc. However, you have not yet submitted 510(k)s as required by 21 CFR 807.81(a)(3)(i). Adding a statement to your labeling that the device software has not undergone FDA review is not sufficient.\nFurthermore, in the regulatory change impact assessment for the Medfusion® Model 4000 Syringe Infusion Pump software update dated April 28, 2023, you identified that a risk-based assessment of the changed device identified new risks or significantly modified risks. Further, you identified that the change either creates or necessitates a new risk control measure or modification of an existing risk control measure for a hazardous situation that could result in significant harm. The changes that you made to the risk control measures in an effort to mitigate the hazards that were the basis for a Class I recall were not submitted to FDA in a required 510(k) even though your own procedure indicates that submission of a 510(k) would be required in this situation. However, you only documented to the file that you had made the change and did not submit the required 510(k).\nYour firm should take prompt action to address the violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which should address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent to: Melissa Michurski, Assistant Director at CDRHenforcement@fda.hhs.gov. Please include in the subject line, CMS case # 702535 when replying. If you have any questions about the contents of this letter, please contact: Demetria Lueneburg, Compliance Officer at Demetria.Lueneburg@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility or associated with your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nMatthew G. Hillebrenner\nDeputy Director\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","ICU Medical","icu-medical-702535-04042025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ficu-medical-702535-04042025","2026-10-26T08:08:57.251119+00:00","2025-04-22","702535","Vivek Jain","2026-08-19T16:52:11.735+00:00","2025-04-04",{"id":156,"raw":157,"subject":15,"body_html":162,"body_text":163,"firm_name":164,"letter_id":165,"created_at":47,"fei_number":21,"letter_url":166,"updated_at":167,"action_type":24,"case_status":25,"posted_date":168,"marcs_cms_no":169,"product_type":28,"closeout_date":170,"issuing_office":84,"recipient_name":171,"body_fetched_at":172,"delivery_method":135,"recipient_title":21,"reference_number":21,"action_taken_date":173,"medical_device_id":21,"response_letter_date":21},2483,[158,159,160,84,15,13,161,13],"\u003Ctime datetime=\"2022-08-30T13:20:00Z\">08\u002F30\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-08-03T04:00:00Z\">08\u002F03\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fusa-medical-llc-631500-08032022\">USA Medical LLC\u003C\u002Fa>","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fusa-medical-llc-631500-02062023\">\u003Ctime datetime=\"2023-02-09T05:00:00Z\">02\u002F09\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Damon H. Roberts\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u002FOwner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>USA Medical LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1220 Texan Trail, Suite 205\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Grapevine\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>76051-4164\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:damon@USAMedicalllc.com\"> damon@USAMedicalllc.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS # 631500\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 3, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Roberts:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at USA Medical LLC (USA Medical), located at 1220 Texan Trail, Suite 205, Grapevine, TX from February 28 through March 15, 2022. During the inspection, FDA investigators determined that your firm is a medical device manufacturer and distributor of SARS-CoV-2 Antigen Rapid Test kits distributed under the names SARS-COV-2 Antigen Rapid Test, \u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID-19 Ag Rapid Test\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> (hereafter, collectively referred to as “COVID-19 Tests”). Based on our review, your COVID-19 Tests are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that the COVID-19 Tests have been distributed in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, these products are adulterated within the meaning of section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\u003C\u002Fp>\n\n\u003Cp>Your products are also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because labeling distributed with these products included statements that the products are authorized for use under an Emergency Use Authorization (EUA). These statements create a false impression that your products have been approved or authorized for emergency use by FDA and are misleading. As discussed above, none of your COVID-19 Test Kits have been approved, cleared, or authorized for emergency use by FDA.\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed products that are intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to prevent the distribution of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\">https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u003C\u002Fa>. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that these COVID-19 Tests are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, in manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We note that you have not responded to the Form FDA 483, List of Inspectional Observations issued to your firm initially on March 15, 2022, and, again in annotated form, on March 17, 2022. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish procedures for acceptance activities, as required by 21 CFR § 820.80(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm distributed at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> SARS-CoV-2 Antigen Rapid Test kits from 9\u002F30\u002F2021 – 2\u002F24\u002F2022 without establishing procedures for incoming product and finished device acceptance activities to ensure the device(s) conform to specified requirements and meet acceptance criteria, and acceptance records are maintained.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to establish procedures to control product that does not conform to specified requirements, as required by 21 CFR § 820.90(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures to ensure that nonconforming product is identified, documented, evaluated, segregated, and dispositioned. As you repackage and relabel tests and you do not have an authorized Emergency Use Authorization for those products, you do not have procedures regarding these nonconforming products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to establish procedures for control and distribution of finished devices, as required by 21 CFR § 820.160(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established and maintained procedures for the control and distribution of your SARS-CoV-2 Antigen Rapid Qualitative Test system to ensure only devices approved for release are distributed, and that purchase orders are reviewed to ensure that ambiguities and errors are resolved before devices are released for distribution. You distributed more than \u003Cstrong>(b)(4)\u003C\u002Fstrong> test kits from 9\u002F30\u002F2021 - 2\u002F24\u002F2022 to customers in the United States and did not review and approve the products prior to release\u002Fdistribution.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to establish procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR § 820.50.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for evaluation of suppliers, including the quality requirements that must be met by suppliers, to ensure that received products and services conform to specified requirements. The firm did not evaluate the manufacturers of the SARS-CoV-2 Antigen Rapid Test kits based on their ability to meet specified requirements, including quality requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to establish procedures for corrective and preventative action, as required by 21 CFR § 820.100(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for implementing and documenting corrective and preventive action, including requirements for: 1) analyzing quality data sources; 2) investigating the cause of nonconformities; 3) identifying the actions needed to prevent occurrence or recurrence of nonconformities; 4) ensuring actions implemented are effective; 5) documenting changes in methods and procedures; 6) disseminating information related to quality problems to appropriate individuals; and 7) submitting relevant information on quality problems for management review.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR § 820.198(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for complaint handling and documentation to ensure that complaints are: 1) processed in a uniform and timely manner, 2) oral complaints are documented upon receipt, 3) complaints are evaluated to determine if the reported event is required to be submitted to the FDA as a Medical Device Report.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>7. Failure to establish procedures to control environmental conditions as required by 21 CFR § 820.70(c).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures to control environmental conditions to ensure that the SARS-CoV-2 Antigen Rapid Test products (raw materials and finished devices) are stored within the required temperature range(s) and monitored to ensure that any deviations are noted and addressed. Your firm was found to be storing test kits in its loading dock and administrative areas without procedures\u002Frequirements\u002Fmonitoring. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> kit has defined storage requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>8. Failure to establish and maintain adequate procedures to ensure that mix-ups, damage, deterioration, contamination, or other adverse effects to product do not occur during handling as required by 21 CFR § 820.140.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, \u003Cstrong>(b)(4)\u003C\u002Fstrong> boxes containing \u003Cstrong>(b)(4)\u003C\u002Fstrong> Diagnostic Kit SARS-CoV-2 Antigen Rapid Test kits (no batch\u002Flot number identification) of products returned on 2\u002F16\u002F2022 in the common administrative area were observed that had not been identified, documented, or segregated as returned product.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>9. Failure to establish procedures for quality audits as required by 21 CFR § 820.22.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for quality audits to ensure that the quality system complies with the quality system requirements and to determine the effectiveness of the quality system. Quality audits have not been performed since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>10. Failure to establish procedures for management review as required by 21 CFR § 820.20(c).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for management review of the suitability and effectiveness of the quality system. Management reviews have not been conducted since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>11. Failure to establish procedures for training and identifying training needs as required by 21 CFR § 820.25(b).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established training procedures to identify training needs and to ensure that all personnel are trained to adequately perform their responsibilities. Training records are not maintained.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>12. Failure to establish a policy, and objectives for, and commitment to, quality as required by 21 CFR § 820.20(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your Management with executive responsibility has not established it policy and objectives for, and commitment to, quality.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your COVID-19 Tests are misbranded under Section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information regarding the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Failure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not established procedures for timely and effective identification, communication, and evaluation of reportable events; a standardized review process for determining when an event meets reportability criteria; timely submission of MDRs to the FDA; or for compliance with the applicable documentation and recordkeeping requirements.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations. Other federal agencies may take your compliance history into account when considering the award of contracts. Should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices such devices will not be approved until the violations have been corrected. Should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-requestreview-%20fdas-decision-not-issue-certain-export-certificates-devices\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-requestreview-fdas-decision-not-issue-certain-export-certificates-devices\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Note, there are two response time frames specified. You should take immediate action to address any violations relating to your firm’s sale or distribution of the COVID-19 Test Kits and to prevent future violations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19 related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\">https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>Please also notify FDA in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter related to Quality Systems and MDR reporting. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If any corrections and\u002For corrective actions your firm plans to take will require more time, please include a timetable for implementation of those activities. If any corrections and\u002For corrective actions your firm plans to take cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. We will communicate with you regarding your firm’s response(s) and any need to re-inspect your firm’s facility to verify that any appropriate corrections have been made and\u002For corrective actions have been taken.\u003C\u002Fp>\n\n\u003Cp>This response should be sent to: US Food and Drug Administration, Division 3\u002FWest, Office of Medical Device and Radiological Health Operations at oradevices3firmresponse@fda.hhs.gov. Please identify your response with CMS Case # 631500.\u003C\u002Fp>\n\n\u003Cp>If you have questions about the contents of this letter, please contact Compliance Officer Raymond W. Brullo at 949-608-2918, or via email at raymond.brullo@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of any deficiencies at your firm’s facility or associated with your firm’s devices. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and FDA’s implementing regulations. Failure to adequately address the matters discussed in this letter may result in legal action, including without limitation, seizure, and injunction. The specific concerns noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be indicative of, or in addition to, other issues with your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any deficiencies and take prompt actions to correct any violations and bring your products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nTimothy T. Stenzel, M.D., Ph.D. Director\u003Cbr>\nOHT7: Office of In Vitro Diagnostics\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Shari J. Shambaugh\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nDivision 3\u003Cbr>\nOffice of Regulatory Affairs\u003C\u002Fp>\n\n\u003Cp>___________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The “\u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID‐19 Ag Rapid Test” distributed by your firm appears to be the \u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID‐19 Ag Rapid Test manufactured by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. On \u003Cstrong>(b)(4)\u003C\u002Fstrong>, FDA reissued an Emergency Use Authorization (EUA) pursuant to section 564 of the Act, 21 U.S.C § 360bbb‐3, to permit emergency use of \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>COVID‐19 Ag Rapid Test. The test is indicated for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, that meet the requirements to perform high complexity, moderate complexity, or waived tests and in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. However, the EUA does not authorize the distribution of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> COVID‐19 Rapid Test for use outside of these specified settings.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID‐19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID‐19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential%E2%80%90actions\u002Fproclamation%E2%80%90declaring%E2%80%90national%E2%80%90%20emergency-concerning%E2%80%90novel%E2%80%90coronavirus%E2%80%90disease%E2%80%90covid%E2%80%9019%E2%80%90outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential‐actions\u002Fproclamation‐declaring‐national‐ emergency-concerning‐novel‐coronavirus‐disease‐covid‐19‐outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Accessible at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nDamon H. Roberts\n\nRecipient Title\n\nPresident\u002FOwner\n\nUSA Medical LLC\n\n1220 Texan Trail, Suite 205\n\nGrapevine, TX 76051-4164\n\nUnited States\n\ndamon@USAMedicalllc.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS # 631500\n\nAugust 3, 2022\n\nDear Mr. Roberts:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at USA Medical LLC (USA Medical), located at 1220 Texan Trail, Suite 205, Grapevine, TX from February 28 through March 15, 2022. During the inspection, FDA investigators determined that your firm is a medical device manufacturer and distributor of SARS-CoV-2 Antigen Rapid Test kits distributed under the names SARS-COV-2 Antigen Rapid Test, (b)(4) COVID-19 Ag Rapid Test1 (hereafter, collectively referred to as “COVID-19 Tests”). Based on our review, your COVID-19 Tests are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-192 in people, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nOur inspection revealed that the COVID-19 Tests have been distributed in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, these products are adulterated within the meaning of section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\n\nYour products are also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because labeling distributed with these products included statements that the products are authorized for use under an Emergency Use Authorization (EUA). These statements create a false impression that your products have been approved or authorized for emergency use by FDA and are misleading. As discussed above, none of your COVID-19 Test Kits have been approved, cleared, or authorized for emergency use by FDA.\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.3 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.4 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed products that are intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to prevent the distribution of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”5 provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\n\nOur inspection also revealed that these COVID-19 Tests are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, in manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We note that you have not responded to the Form FDA 483, List of Inspectional Observations issued to your firm initially on March 15, 2022, and, again in annotated form, on March 17, 2022. These violations include, but are not limited to, the following:\n\n1. Failure to establish procedures for acceptance activities, as required by 21 CFR § 820.80(a).\n\nSpecifically, your firm distributed at least (b)(4) SARS-CoV-2 Antigen Rapid Test kits from 9\u002F30\u002F2021 – 2\u002F24\u002F2022 without establishing procedures for incoming product and finished device acceptance activities to ensure the device(s) conform to specified requirements and meet acceptance criteria, and acceptance records are maintained.\n\n2. Failure to establish procedures to control product that does not conform to specified requirements, as required by 21 CFR § 820.90(a).\n\nSpecifically, your firm has not established procedures to ensure that nonconforming product is identified, documented, evaluated, segregated, and dispositioned. As you repackage and relabel tests and you do not have an authorized Emergency Use Authorization for those products, you do not have procedures regarding these nonconforming products.\n\n3. Failure to establish procedures for control and distribution of finished devices, as required by 21 CFR § 820.160(a).\n\nSpecifically, your firm has not established and maintained procedures for the control and distribution of your SARS-CoV-2 Antigen Rapid Qualitative Test system to ensure only devices approved for release are distributed, and that purchase orders are reviewed to ensure that ambiguities and errors are resolved before devices are released for distribution. You distributed more than (b)(4) test kits from 9\u002F30\u002F2021 - 2\u002F24\u002F2022 to customers in the United States and did not review and approve the products prior to release\u002Fdistribution.\n\n4. Failure to establish procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR § 820.50.\n\nSpecifically, your firm has not established procedures for evaluation of suppliers, including the quality requirements that must be met by suppliers, to ensure that received products and services conform to specified requirements. The firm did not evaluate the manufacturers of the SARS-CoV-2 Antigen Rapid Test kits based on their ability to meet specified requirements, including quality requirements.\n\n5. Failure to establish procedures for corrective and preventative action, as required by 21 CFR § 820.100(a).\n\nSpecifically, your firm has not established procedures for implementing and documenting corrective and preventive action, including requirements for: 1) analyzing quality data sources; 2) investigating the cause of nonconformities; 3) identifying the actions needed to prevent occurrence or recurrence of nonconformities; 4) ensuring actions implemented are effective; 5) documenting changes in methods and procedures; 6) disseminating information related to quality problems to appropriate individuals; and 7) submitting relevant information on quality problems for management review.\n\n6. Failure to establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR § 820.198(a).\n\nSpecifically, your firm has not established procedures for complaint handling and documentation to ensure that complaints are: 1) processed in a uniform and timely manner, 2) oral complaints are documented upon receipt, 3) complaints are evaluated to determine if the reported event is required to be submitted to the FDA as a Medical Device Report.\n\n7. Failure to establish procedures to control environmental conditions as required by 21 CFR § 820.70(c).\n\nSpecifically, your firm has not established procedures to control environmental conditions to ensure that the SARS-CoV-2 Antigen Rapid Test products (raw materials and finished devices) are stored within the required temperature range(s) and monitored to ensure that any deviations are noted and addressed. Your firm was found to be storing test kits in its loading dock and administrative areas without procedures\u002Frequirements\u002Fmonitoring. The (b)(4) kit has defined storage requirements.\n\n8. Failure to establish and maintain adequate procedures to ensure that mix-ups, damage, deterioration, contamination, or other adverse effects to product do not occur during handling as required by 21 CFR § 820.140.\n\nSpecifically, (b)(4) boxes containing (b)(4) Diagnostic Kit SARS-CoV-2 Antigen Rapid Test kits (no batch\u002Flot number identification) of products returned on 2\u002F16\u002F2022 in the common administrative area were observed that had not been identified, documented, or segregated as returned product.\n\n9. Failure to establish procedures for quality audits as required by 21 CFR § 820.22.\n\nSpecifically, your firm has not established procedures for quality audits to ensure that the quality system complies with the quality system requirements and to determine the effectiveness of the quality system. Quality audits have not been performed since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\n\n10. Failure to establish procedures for management review as required by 21 CFR § 820.20(c).\n\nSpecifically, your firm has not established procedures for management review of the suitability and effectiveness of the quality system. Management reviews have not been conducted since the firm began to distribute SARS-CoV-2 Antigen Rapid Test kits in approximately March 2020.\n\n11. Failure to establish procedures for training and identifying training needs as required by 21 CFR § 820.25(b).\n\nSpecifically, your firm has not established training procedures to identify training needs and to ensure that all personnel are trained to adequately perform their responsibilities. Training records are not maintained.\n\n12. Failure to establish a policy, and objectives for, and commitment to, quality as required by 21 CFR § 820.20(a).\n\nSpecifically, your Management with executive responsibility has not established it policy and objectives for, and commitment to, quality.\n\nOur inspection also revealed that your COVID-19 Tests are misbranded under Section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information regarding the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting.\n\nFailure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\n\nSpecifically, your firm has not established procedures for timely and effective identification, communication, and evaluation of reportable events; a standardized review process for determining when an event meets reportability criteria; timely submission of MDRs to the FDA; or for compliance with the applicable documentation and recordkeeping requirements.\n\nYour firm should take prompt action to address any violations. Other federal agencies may take your compliance history into account when considering the award of contracts. Should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices such devices will not be approved until the violations have been corrected. Should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at: https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-requestreview-fdas-decision-not-issue-certain-export-certificates-devices.\n\nNote, there are two response time frames specified. You should take immediate action to address any violations relating to your firm’s sale or distribution of the COVID-19 Test Kits and to prevent future violations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19 related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so.\n\nFDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nPlease also notify FDA in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter related to Quality Systems and MDR reporting. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If any corrections and\u002For corrective actions your firm plans to take will require more time, please include a timetable for implementation of those activities. If any corrections and\u002For corrective actions your firm plans to take cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. We will communicate with you regarding your firm’s response(s) and any need to re-inspect your firm’s facility to verify that any appropriate corrections have been made and\u002For corrective actions have been taken.\n\nThis response should be sent to: US Food and Drug Administration, Division 3\u002FWest, Office of Medical Device and Radiological Health Operations at oradevices3firmresponse@fda.hhs.gov. Please identify your response with CMS Case # 631500.\n\nIf you have questions about the contents of this letter, please contact Compliance Officer Raymond W. Brullo at 949-608-2918, or via email at raymond.brullo@fda.hhs.gov\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of any deficiencies at your firm’s facility or associated with your firm’s devices. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and FDA’s implementing regulations. Failure to adequately address the matters discussed in this letter may result in legal action, including without limitation, seizure, and injunction. The specific concerns noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be indicative of, or in addition to, other issues with your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any deficiencies and take prompt actions to correct any violations and bring your products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nTimothy T. Stenzel, M.D., Ph.D. Director\n\nOHT7: Office of In Vitro Diagnostics\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n\u002FS\u002F\n\nShari J. Shambaugh\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nDivision 3\n\nOffice of Regulatory Affairs\n\n___________________________\n\n1 The “(b)(4) COVID‐19 Ag Rapid Test” distributed by your firm appears to be the (b)(4) COVID‐19 Ag Rapid Test manufactured by (b)(4). On (b)(4), FDA reissued an Emergency Use Authorization (EUA) pursuant to section 564 of the Act, 21 U.S.C § 360bbb‐3, to permit emergency use of (b)(4) COVID‐19 Ag Rapid Test. The test is indicated for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, that meet the requirements to perform high complexity, moderate complexity, or waived tests and in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. However, the EUA does not authorize the distribution of the (b)(4) COVID‐19 Rapid Test for use outside of these specified settings.\n\n2 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID‐19).\n\n3 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n4 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID‐19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential‐actions\u002Fproclamation‐declaring‐national‐ emergency-concerning‐novel‐coronavirus‐disease‐covid‐19‐outbreak\u002F.\n\n5 Accessible at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload.","USA Medical LLC","usa-medical-llc-631500-08032022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fusa-medical-llc-631500-08032022","2026-10-26T08:10:18.402099+00:00","2022-08-30","631500","2023-02-09","Damon H. Roberts","2026-08-20T01:37:57.067+00:00","2022-08-03",{"id":175,"raw":176,"subject":105,"body_html":180,"body_text":181,"firm_name":182,"letter_id":183,"created_at":147,"fei_number":21,"letter_url":184,"updated_at":185,"action_type":24,"case_status":50,"posted_date":186,"marcs_cms_no":187,"product_type":188,"closeout_date":21,"issuing_office":104,"recipient_name":189,"body_fetched_at":190,"delivery_method":76,"recipient_title":21,"reference_number":21,"action_taken_date":191,"medical_device_id":21,"response_letter_date":21},778,[177,178,179,104,105,13,13,13],"\u003Ctime datetime=\"2025-07-15T04:00:00Z\">07\u002F15\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-07-09T04:00:00Z\">07\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcovalent-medical-695839-07092025\">Covalent Medical \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Clint Worley, COO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Covalent Medical \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>24600 Millstream Drive, Ste 410\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Aldie\u003C\u002Fspan>, \u003Cspan>VA\u003C\u002Fspan> \u003Cspan>20105\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:CWORLEY@focusvitamins.com\"> CWORLEY@focusvitamins.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>July 9, 2025\u003C\u002Fp>\u003Cp>RE: 695839\u003C\u002Fp>\u003Cp>Dear Mr. Worley:\u003C\u002Fp>\u003Cp>This letter is to advise you that on September 27, 2024 the U.S. Food and Drug Administration (FDA) reviewed your product labeling, including on your website at the internet address, www.focusvitamins.com, where your FOCUS PI Post-Injection Eye Drops product is available for purchase in the United States without a prescription. We also reviewed your social media sites on Instagram (https:\u002F\u002Fwww.instagram.com\u002Ffocus_vitamins\u002F) and Facebook (https:\u002F\u002Fwww.facebook.com\u002Ffocusvitamins), both of which direct consumers to your website to purchase your product(s).\u003C\u002Fp>\u003Cp>Based on our review, your FOCUS PI Post-Injection Eye Drops product is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d). In addition, this product is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved New Drug and Misbranded Drug Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your FOCUS PI Post-Injection Eye Drops product is a “drug” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples of claims from the product labeling, your website, and your social media posts that provide evidence of the intended use (as defined in 21 CFR 201.128) of this product as a drug include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>“FOCUS PI … Post-Injection Eye Drops” [product name on principal display panel (PDP) of product carton labeling and product label]\u003C\u002Fp>\u003Cp>“Long Lasting Relief, Clinically proven to lubricate, hydrate, &amp; relieve the eyes from irritation” [from PDP on product carton labeling]\u003C\u002Fp>\u003Cp>“\u003Cstrong>Use\u003C\u002Fstrong> ▪ For use as a lubricant to prevent further irritation or to relieve dryness of the eye” [from Drug Facts panel on product carton labeling]\u003C\u002Fp>\u003Cp>\u003Cstrong>“Designed for Post-injection Irritation Relief”\u003C\u002Fstrong> [from your website https:\u002F\u002Ffocusvitamins.com\u002Fproducts\u002Ffocus-pi (last visited September 2024)]\u003C\u002Fp>\u003Cp>\u003Cstrong>“Focus PI (Post-injection) eye drops provide relief from irritation associated with eye injections.\u003C\u002Fstrong> As the first product of its kind, Focus Vitamins and founding ophthalmologists formulated Focus PI to help soothe any eye discomfort patients might experience, including irritation and dry eye symptoms after eye injections.” [from your website https:\u002F\u002Ffocusvitamins.com\u002Fproducts\u002Ffocus-pi (last visited September 2024)]\u003C\u002Fp>\u003Cp>“Focus PI is formulated and safe for use immediately after eye injections and\u002For during the following days when your eyes are irritated.” [from your website under FAQS: When should I use Focus PI? https:\u002F\u002Ffocusvitamins.com\u002Fproducts\u002Ffocus-pi (last visited September 2024)]\u003C\u002Fp>\u003Cp>“If you get eye injections, Focus PI is for you! Focus PI are post-injection eye drops that are clinically proven to lubricate, hydrate, &amp; relieve the eyes from irritation that comes after ocular injections.” [from Instagram post with 2 likes on January 23, 2023 https:\u002F\u002Fwww.instagram.com\u002Fp\u002FCn0P_CpMZJM\u002F (last visited September 2024)]\u003C\u002Fp>\u003Cp>“Searching for post-injection relief for your eyes? Focus PI eye drops are clinically proven to lubricate, hydrate, and relieve the eyes from irritation following ocular injections. Shop now…” [from Facebook post on August 15, 2023 https:\u002F\u002Fwww.facebook.com\u002Ffocusvitamins (last visited September 2024)]\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the above evidence of intended use, your FOCUS PI Post-Injection Eye Drops product is intended for use as an ophthalmic demulcent (lubricant) drug product. As described below, this drug product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for your FOCUS PI Post-Injection Eye Drops drug product.\u003C\u002Fp>\u003Cp>Your drug product is marketed as an ophthalmic demulcent drug product and is subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which generally governs nonprescription drugs marketed without an approved application. Under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as “over-the-counter (OTC) monograph drugs”—may be legally marketed if they meet applicable requirements. With respect to nonprescription ophthalmic drug products, such as your FOCUS PI Post-Injection Eye Drops drug product, in order to be GRASE and not a new drug, the product must, among other things, conform to the conditions in the applicable OTC monograph, here OTC Monograph M018: Ophthalmic Drug Products for Over-the-Counter Human Use (hereinafter M018).\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> However, your FOCUS PI Post-Injection Eye Drops drug product does not conform to the conditions specified in M018 for the reasons described below.\u003C\u002Fp>\u003Cp>Specifically, the statements made in your product labeling on your website and social media sites include claims for relief of post-injection irritation, which are not permitted indications for ophthalmic demulcent drug products in monograph M018.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Thus, your FOCUS PI Post-Injection Eye Drops drug product does not comply with the applicable conditions specified in Monograph M018 and has not otherwise been found GRASE.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, this product is a new drug within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&amp;C Act under which this product would be legally marketed without an approved application. Because there is no approved application in effect for this product, this product is an unapproved new drug. The introduction or delivery for introduction into interstate commerce of this unapproved new drug product violates sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>\u003Cstrong>Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Additionally, your FOCUS PI Post-Injection Eye Drops drug product is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because this product is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your product(s). You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your product(s) are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “695839” in the subject line of your email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>Food and Drug Administration\u003C\u002Fp>\u003Cp>_____________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> M018 reflects the monograph conditions as set forth in the relevant final order(s) established and in effect under section 505G; see Order ID OTC000023, available at FDA’s website OTC Monographs@FDA.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Under M018.60, “Labeling of ophthalmic demulcent drug products”, the permitted indications are listed in M018.60(b).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that the FOCUS PI Post-Injection Eye Drops drug product is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling, nor has FDA determined these drug products to be GRASE pursuant to an order issued under section 505G(b) of the FD&amp;C Act.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nClint Worley, COO\n\nCovalent Medical\n\n24600 Millstream Drive, Ste 410\n\nAldie, VA 20105\n\nUnited States\n\nCWORLEY@focusvitamins.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nJuly 9, 2025\nRE: 695839\nDear Mr. Worley:\nThis letter is to advise you that on September 27, 2024 the U.S. Food and Drug Administration (FDA) reviewed your product labeling, including on your website at the internet address, www.focusvitamins.com, where your FOCUS PI Post-Injection Eye Drops product is available for purchase in the United States without a prescription. We also reviewed your social media sites on Instagram (https:\u002F\u002Fwww.instagram.com\u002Ffocus_vitamins\u002F) and Facebook (https:\u002F\u002Fwww.facebook.com\u002Ffocusvitamins), both of which direct consumers to your website to purchase your product(s).\nBased on our review, your FOCUS PI Post-Injection Eye Drops product is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d). In addition, this product is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\nUnapproved New Drug and Misbranded Drug Violations\nYour FOCUS PI Post-Injection Eye Drops product is a “drug” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body.\nExamples of claims from the product labeling, your website, and your social media posts that provide evidence of the intended use (as defined in 21 CFR 201.128) of this product as a drug include, but may not be limited to, the following:\n“FOCUS PI … Post-Injection Eye Drops” [product name on principal display panel (PDP) of product carton labeling and product label]\n“Long Lasting Relief, Clinically proven to lubricate, hydrate, & relieve the eyes from irritation” [from PDP on product carton labeling]\n“Use ▪ For use as a lubricant to prevent further irritation or to relieve dryness of the eye” [from Drug Facts panel on product carton labeling]\n“Designed for Post-injection Irritation Relief” [from your website https:\u002F\u002Ffocusvitamins.com\u002Fproducts\u002Ffocus-pi (last visited September 2024)]\n“Focus PI (Post-injection) eye drops provide relief from irritation associated with eye injections. As the first product of its kind, Focus Vitamins and founding ophthalmologists formulated Focus PI to help soothe any eye discomfort patients might experience, including irritation and dry eye symptoms after eye injections.” [from your website https:\u002F\u002Ffocusvitamins.com\u002Fproducts\u002Ffocus-pi (last visited September 2024)]\n“Focus PI is formulated and safe for use immediately after eye injections and\u002For during the following days when your eyes are irritated.” [from your website under FAQS: When should I use Focus PI? https:\u002F\u002Ffocusvitamins.com\u002Fproducts\u002Ffocus-pi (last visited September 2024)]\n“If you get eye injections, Focus PI is for you! Focus PI are post-injection eye drops that are clinically proven to lubricate, hydrate, & relieve the eyes from irritation that comes after ocular injections.” [from Instagram post with 2 likes on January 23, 2023 https:\u002F\u002Fwww.instagram.com\u002Fp\u002FCn0P_CpMZJM\u002F (last visited September 2024)]\n“Searching for post-injection relief for your eyes? Focus PI eye drops are clinically proven to lubricate, hydrate, and relieve the eyes from irritation following ocular injections. Shop now…” [from Facebook post on August 15, 2023 https:\u002F\u002Fwww.facebook.com\u002Ffocusvitamins (last visited September 2024)]\nUnapproved New Drug Violations\nBased on the above evidence of intended use, your FOCUS PI Post-Injection Eye Drops product is intended for use as an ophthalmic demulcent (lubricant) drug product. As described below, this drug product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for your FOCUS PI Post-Injection Eye Drops drug product.\nYour drug product is marketed as an ophthalmic demulcent drug product and is subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which generally governs nonprescription drugs marketed without an approved application. Under section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as “over-the-counter (OTC) monograph drugs”—may be legally marketed if they meet applicable requirements. With respect to nonprescription ophthalmic drug products, such as your FOCUS PI Post-Injection Eye Drops drug product, in order to be GRASE and not a new drug, the product must, among other things, conform to the conditions in the applicable OTC monograph, here OTC Monograph M018: Ophthalmic Drug Products for Over-the-Counter Human Use (hereinafter M018).1 However, your FOCUS PI Post-Injection Eye Drops drug product does not conform to the conditions specified in M018 for the reasons described below.\nSpecifically, the statements made in your product labeling on your website and social media sites include claims for relief of post-injection irritation, which are not permitted indications for ophthalmic demulcent drug products in monograph M018.2\nThus, your FOCUS PI Post-Injection Eye Drops drug product does not comply with the applicable conditions specified in Monograph M018 and has not otherwise been found GRASE.3 Accordingly, this product is a new drug within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&C Act under which this product would be legally marketed without an approved application. Because there is no approved application in effect for this product, this product is an unapproved new drug. The introduction or delivery for introduction into interstate commerce of this unapproved new drug product violates sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nMisbranded Drug Violations\nAdditionally, your FOCUS PI Post-Injection Eye Drops drug product is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because this product is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your product(s). You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your product(s) are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction.\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “695839” in the subject line of your email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs & Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nFood and Drug Administration\n_____________________________\n1 M018 reflects the monograph conditions as set forth in the relevant final order(s) established and in effect under section 505G; see Order ID OTC000023, available at FDA’s website OTC Monographs@FDA.\n2 Under M018.60, “Labeling of ophthalmic demulcent drug products”, the permitted indications are listed in M018.60(b).\n3 FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that the FOCUS PI Post-Injection Eye Drops drug product is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling, nor has FDA determined these drug products to be GRASE pursuant to an order issued under section 505G(b) of the FD&C Act.","Covalent Medical","covalent-medical-695839-07092025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcovalent-medical-695839-07092025","2026-10-26T08:08:18.901487+00:00","2025-07-15","695839","Drugs Over-the-Counter Drugs","Clint Worley, COO","2026-08-19T16:35:27.665+00:00","2025-07-09",9,{"510k":194,"classification":195,"enforcement":196,"event":197,"event_backfill":198,"pma":199,"warning_letter":200},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]